Skip to main content
Psychedex
Sources
28
1 strong · 19 moderate · 8 weak

Studies and references cited across this article, graded by evidence strength.

Claims checked
139
125verified2partial11inconclusive1not supported

Inconclusive means the cited source neither confirms nor refutes the claim — a lower-confidence badge, not an error.

Generated
May 8, 2026 · pipeline-v5
Values approved
86/86 (100%)

Data points an editor reviewed and accepted for publication.

01

Value Provenance

Dosing

insufflatedtrace

FieldPublishedAI ProposedConfidence
Threshold5 μg5 μglow
Low5–15 μg5–15 μglow
Common15–40 μg15–40 μglow
Strong40–80 μg40–80 μglow
Heavy80+ μg80+ μglow
Editorial

NO HUMAN DOSE DATA EXIST. Values derived by structural analogy from fentanyl insufflated dose ranges (~25-200 μg) divided by approximately 3.7× potency ratio (rat IV ED50 data, De Luca et al. 2022), then conservatively lowered further because: (1) the active metabolite N-desethyl isotonitazene is more potent than the parent, (2) slow MOR dissociation kinetics reduce naloxone efficacy, and (3) street product has been sold at >95% purity undiluted. These values are EDITORIAL FLAGS — no safe dose exists for unsupervised use. Reviewer must assess before publication.

Reasoning

NO HUMAN DOSE DATA EXIST. Values derived by structural analogy from fentanyl insufflated dose ranges (~25-200 μg) divided by approximately 3.7× potency ratio (rat IV ED50 data, De Luca et al. 2022), then conservatively lowered further because: (1) the active metabolite N-desethyl isotonitazene is more potent than the parent, (2) slow MOR dissociation kinetics reduce naloxone efficacy, and (3) street product has been sold at >95% purity undiluted. These values are EDITORIAL FLAGS — no safe dose exists for unsupervised use. Reviewer must assess before publication.

Evidence basis: structural_analogy

Duration

insufflated

FieldPublishedAI ProposedConfidence
Onsettrace1–5 minutes1–5 minuteslow
Editorial

No human duration data exist for isotonitazene by any ROA. Insufflated onset inferred from fentanyl nasal onset (~2-5 min) with adjustment for higher potency. Reference compound: fentanyl insufflated.

Reasoning

No human duration data exist for isotonitazene by any ROA. Insufflated onset inferred from fentanyl nasal onset (~2-5 min) with adjustment for higher potency. Reference compound: fentanyl insufflated.

Evidence basis: structural_analogy

Come uptrace2–10 minutes2–10 minuteslow
Editorial

Class-inferred from potent short-acting opioids (fentanyl insufflated). Widened range to account for unknown absorption and metabolite kinetics.

Reasoning

Class-inferred from potent short-acting opioids (fentanyl insufflated). Widened range to account for unknown absorption and metabolite kinetics.

Evidence basis: structural_analogy

Peaktrace10–30 minutes10–30 minuteslow
Editorial

Inferred from fentanyl insufflated peak (~10-20 min), widened upward to account for slow MOR dissociation and active metabolite accumulation. Reference compound: fentanyl.

Reasoning

Inferred from fentanyl insufflated peak (~10-20 min), widened upward to account for slow MOR dissociation and active metabolite accumulation. Reference compound: fentanyl.

Evidence basis: structural_analogy

Offsettrace30–90 minutes30–90 minuteslow
Editorial

Inferred from fentanyl insufflated offset, extended to account for slow receptor dissociation kinetics (Alhosan et al. 2025) and active metabolite contribution.

Reasoning

Inferred from fentanyl insufflated offset, extended to account for slow receptor dissociation kinetics (Alhosan et al. 2025) and active metabolite contribution.

Evidence basis: structural_analogy

Totaltrace1–3 hours1–3 hourslow
Editorial

Inferred from fentanyl insufflated total subjective duration (~1-2h), extended to account for slow MOR dissociation and N-desethyl isotonitazene metabolite contribution. No human data exist.

Reasoning

Inferred from fentanyl insufflated total subjective duration (~1-2h), extended to account for slow MOR dissociation and N-desethyl isotonitazene metabolite contribution. No human data exist.

Evidence basis: structural_analogy

After effectstrace2–8 hours2–8 hourslow
Editorial

Residual sedation and subclinical respiratory depression may persist for hours due to active metabolite. Widened from fentanyl (~1-4h aftereffects) given pharmacological unknowns.

Reasoning

Residual sedation and subclinical respiratory depression may persist for hours due to active metabolite. Widened from fentanyl (~1-4h aftereffects) given pharmacological unknowns.

Evidence basis: structural_analogy

Safety

Toxicity Profiletrace

FieldPublishedAI ProposedConfidence
Acutecriticalcriticalmedium
Chronicmoderatemoderatemedium
Organs Affectedpulmonary, neurological, cardiovascularpulmonary, neurological, cardiovascularmedium
Editorial

Acute toxicity rated critical based on published fatal case series (Mueller et al. 2021; Vevelstad et al. 2026) — documented fatalities at sub-ng/mL blood concentrations, no therapeutic index, naloxone resistance. Chronic toxicity rated moderate: no isotonitazene-specific chronic data exist; class-extrapolated from potent MOR full agonists (fentanyl, heroin) where chronic organ damage is well-documented, then discounted one level per evidence discount rule for structural inference.

Reasoning

Acute toxicity rated critical based on published fatal case series (Mueller et al. 2021; Vevelstad et al. 2026) — documented fatalities at sub-ng/mL blood concentrations, no therapeutic index, naloxone resistance. Chronic toxicity rated moderate: no isotonitazene-specific chronic data exist; class-extrapolated from potent MOR full agonists (fentanyl, heroin) where chronic organ damage is well-documented, then discounted one level per evidence discount rule for structural inference.

Evidence basis: published_case_series

Dependence Profiletrace

FieldPublishedAI ProposedConfidence
Physicalhighhighmedium
Psychologicalhighhighmedium
Compulsive Redosinghighhighmedium
Dose Escalationhighhighmedium
Editorial

Animal data provide strong evidence for high dependence liability: CPP at 0.01–0.05 mg/kg, ~200% NAc dopamine elevation, and authors' conclusion of 'high risk of forming drug dependence' (Tomiyama & Funada 2025). Physical and psychological dependence ratings are class-inferred from potent MOR full agonists (fentanyl, heroin) — no human dependence data exist for isotonitazene specifically.

Reasoning

Animal data provide strong evidence for high dependence liability: CPP at 0.01–0.05 mg/kg, ~200% NAc dopamine elevation, and authors' conclusion of 'high risk of forming drug dependence' (Tomiyama & Funada 2025). Physical and psychological dependence ratings are class-inferred from potent MOR full agonists (fentanyl, heroin) — no human dependence data exist for isotonitazene specifically.

Evidence basis: animal_study

Withdrawal Profiletrace

FieldPublishedAI ProposedConfidence
Severitysevereseverelow
Symptomsdysphoria, anxiety, pain hypersensitivity, autonomic instability (sweating, piloerection, tachycardia), gastrointestinal distress, insomnia, restlessness, lacrimation, rhinorrheadysphoria, anxiety, pain hypersensitivity, autonomic instability (sweating, piloerection, tachycardia), gastrointestinal distress, insomnia, restlessness, lacrimation, rhinorrhealow
FatalNoNolow
Medical SupervisionRequiredRequiredlow
Editorial

No human withdrawal data exist for isotonitazene. All withdrawal parameters are class-inferred from potent MOR full agonists (fentanyl: onset 6-12h, acute 5-10 days; heroin: similar profile). Medical supervision recommended due to extreme potency and unpredictable metabolite contribution. Protracted withdrawal may extend weeks to months (class inference).

Reasoning

No human withdrawal data exist for isotonitazene. All withdrawal parameters are class-inferred from potent MOR full agonists (fentanyl: onset 6-12h, acute 5-10 days; heroin: similar profile). Medical supervision recommended due to extreme potency and unpredictable metabolite contribution. Protracted withdrawal may extend weeks to months (class inference).

Evidence basis: animal_study

Tolerance Profiletrace

FieldPublishedAI ProposedConfidence
Builduprapidrapidlow
Half-life5 days5 dayslow
Full Reset14 days14 dayslow
Cross-tolerancesmorphine, fentanyl, heroin, oxycodone, hydromorphone, methadone, all MOR full agonistsmorphine, fentanyl, heroin, oxycodone, hydromorphone, methadone, all MOR full agonistslow
Editorial

No isotonitazene-specific tolerance data exist. Rapid buildup inferred from potent MOR full agonist class (fentanyl, heroin). Tolerance half-life ~5 days and full reset ~14 days are class-analog estimates from fentanyl. All values should be treated as provisional structural analogy estimates.

Reasoning

No isotonitazene-specific tolerance data exist. Rapid buildup inferred from potent MOR full agonist class (fentanyl, heroin). Tolerance half-life ~5 days and full reset ~14 days are class-analog estimates from fentanyl. All values should be treated as provisional structural analogy estimates.

Evidence basis: structural_analogy

Effects & Profile

Contraindications

FieldPublishedAI ProposedConfidence
other Concurrent benzodiazepine usetraceabsoluteabsolutehigh
Editorial

Directly supported by forensic epidemiology — >90% polydrug in nitazene fatalities, 50% with designer benzodiazepines (Vevelstad et al. 2026). Pharmacodynamic mechanism is well-established.

Reasoning

Directly supported by forensic epidemiology — >90% polydrug in nitazene fatalities, 50% with designer benzodiazepines (Vevelstad et al. 2026). Pharmacodynamic mechanism is well-established.

other Concurrent opioid usetraceabsoluteabsolutehigh
Editorial

Documented in polydrug forensic cases (Montanari et al. 2022; Papsun et al. 2022). Pharmacological mechanism is shared MOR agonism at brainstem respiratory centers.

Reasoning

Documented in polydrug forensic cases (Montanari et al. 2022; Papsun et al. 2022). Pharmacological mechanism is shared MOR agonism at brainstem respiratory centers.

other Concurrent alcohol usetraceabsoluteabsolutehigh
Editorial

Supported by forensic epidemiology documenting alcohol in polydrug nitazene fatalities (Vevelstad et al. 2026). Synergistic CNS depression mechanism is well-established for opioid-alcohol combinations.

Reasoning

Supported by forensic epidemiology documenting alcohol in polydrug nitazene fatalities (Vevelstad et al. 2026). Synergistic CNS depression mechanism is well-established for opioid-alcohol combinations.

other Concurrent MAOI usetraceabsoluteabsolutelow
Editorial

Class-level opioid contraindication inferred from MOR full agonist pharmacology. No isotonitazene-specific data. Reference compounds: fentanyl, morphine.

Reasoning

Class-level opioid contraindication inferred from MOR full agonist pharmacology. No isotonitazene-specific data. Reference compounds: fentanyl, morphine.

respiratory Respiratory compromisetraceabsoluteabsolutemedium
Editorial

Class-inferred from MOR full agonist pharmacology. Mechanistically sound: respiratory depression is the primary lethal mechanism in all documented isotonitazene fatalities (Mueller et al. 2021). Reference compounds: fentanyl, morphine.

Reasoning

Class-inferred from MOR full agonist pharmacology. Mechanistically sound: respiratory depression is the primary lethal mechanism in all documented isotonitazene fatalities (Mueller et al. 2021). Reference compounds: fentanyl, morphine.

hepatic Hepatic impairmenttracerelativerelativelow
Editorial

Class-inferred from metabolic pathway data (Taoussi et al. 2024). CYP enzyme involvement itself is inferred from substrate structural features, not directly measured. Reference compounds: fentanyl (CYP3A4 substrate).

Reasoning

Class-inferred from metabolic pathway data (Taoussi et al. 2024). CYP enzyme involvement itself is inferred from substrate structural features, not directly measured. Reference compounds: fentanyl (CYP3A4 substrate).

renal Renal impairmenttracerelativerelativelow
Editorial

Class-inferred from MOR full agonist pharmacology and general pharmacokinetic principles. No isotonitazene-specific renal data. Reference compounds: morphine (active metabolite accumulation in renal failure).

Reasoning

Class-inferred from MOR full agonist pharmacology and general pharmacokinetic principles. No isotonitazene-specific renal data. Reference compounds: morphine (active metabolite accumulation in renal failure).

Timeline Phases

intravenous

FieldPublishedAI ProposedConfidence
Peaktrace300–1800 sec(i=1.00)300–1800 sec(i=1.00)low
Editorial

No human pharmacokinetic or duration-of-action data exist for isotonitazene by any route. All timeline phases are class-inferred from potent short-to-medium-acting IV opioids (fentanyl: onset seconds, peak 3-5 min, total 30-90 min). Durations widened to account for isotonitazene's slow MOR dissociation kinetics and the contribution of the more-potent active metabolite N-desethyl isotonitazene, which may extend duration unpredictably. Reference compound: fentanyl IV.

Reasoning

No human pharmacokinetic or duration-of-action data exist for isotonitazene by any route. All timeline phases are class-inferred from potent short-to-medium-acting IV opioids (fentanyl: onset seconds, peak 3-5 min, total 30-90 min). Durations widened to account for isotonitazene's slow MOR dissociation kinetics and the contribution of the more-potent active metabolite N-desethyl isotonitazene, which may extend duration unpredictably. Reference compound: fentanyl IV.

Evidence basis: structural_analogy

Plateautrace900–2700 sec(i=0.50)900–2700 sec(i=0.50)low
Editorial

No human pharmacokinetic or duration-of-action data exist for isotonitazene by any route. All timeline phases are class-inferred from potent short-to-medium-acting IV opioids (fentanyl: onset seconds, peak 3-5 min, total 30-90 min). Durations widened to account for isotonitazene's slow MOR dissociation kinetics and the contribution of the more-potent active metabolite N-desethyl isotonitazene, which may extend duration unpredictably. Reference compound: fentanyl IV.

Reasoning

No human pharmacokinetic or duration-of-action data exist for isotonitazene by any route. All timeline phases are class-inferred from potent short-to-medium-acting IV opioids (fentanyl: onset seconds, peak 3-5 min, total 30-90 min). Durations widened to account for isotonitazene's slow MOR dissociation kinetics and the contribution of the more-potent active metabolite N-desethyl isotonitazene, which may extend duration unpredictably. Reference compound: fentanyl IV.

Evidence basis: structural_analogy

Resolutiontrace1800–3600 sec(i=0.20)1800–3600 sec(i=0.20)low
Editorial

No human pharmacokinetic or duration-of-action data exist for isotonitazene by any route. All timeline phases are class-inferred from potent short-to-medium-acting IV opioids (fentanyl: onset seconds, peak 3-5 min, total 30-90 min). Durations widened to account for isotonitazene's slow MOR dissociation kinetics and the contribution of the more-potent active metabolite N-desethyl isotonitazene, which may extend duration unpredictably. Reference compound: fentanyl IV.

Reasoning

No human pharmacokinetic or duration-of-action data exist for isotonitazene by any route. All timeline phases are class-inferred from potent short-to-medium-acting IV opioids (fentanyl: onset seconds, peak 3-5 min, total 30-90 min). Durations widened to account for isotonitazene's slow MOR dissociation kinetics and the contribution of the more-potent active metabolite N-desethyl isotonitazene, which may extend duration unpredictably. Reference compound: fentanyl IV.

Evidence basis: structural_analogy

Afterglowtrace3600–14400 sec(i=0.05)3600–14400 sec(i=0.05)low
Editorial

No human pharmacokinetic or duration-of-action data exist for isotonitazene by any route. All timeline phases are class-inferred from potent short-to-medium-acting IV opioids (fentanyl: onset seconds, peak 3-5 min, total 30-90 min). Durations widened to account for isotonitazene's slow MOR dissociation kinetics and the contribution of the more-potent active metabolite N-desethyl isotonitazene, which may extend duration unpredictably. Reference compound: fentanyl IV.

Reasoning

No human pharmacokinetic or duration-of-action data exist for isotonitazene by any route. All timeline phases are class-inferred from potent short-to-medium-acting IV opioids (fentanyl: onset seconds, peak 3-5 min, total 30-90 min). Durations widened to account for isotonitazene's slow MOR dissociation kinetics and the contribution of the more-potent active metabolite N-desethyl isotonitazene, which may extend duration unpredictably. Reference compound: fentanyl IV.

Evidence basis: structural_analogy

Onsettrace15–60 sec(i=0.05)15–60 sec(i=0.05)low
Editorial

No human pharmacokinetic or duration-of-action data exist for isotonitazene by any route. All timeline phases are class-inferred from potent short-to-medium-acting IV opioids (fentanyl: onset seconds, peak 3-5 min, total 30-90 min). Durations widened to account for isotonitazene's slow MOR dissociation kinetics and the contribution of the more-potent active metabolite N-desethyl isotonitazene, which may extend duration unpredictably. Reference compound: fentanyl IV.

Reasoning

No human pharmacokinetic or duration-of-action data exist for isotonitazene by any route. All timeline phases are class-inferred from potent short-to-medium-acting IV opioids (fentanyl: onset seconds, peak 3-5 min, total 30-90 min). Durations widened to account for isotonitazene's slow MOR dissociation kinetics and the contribution of the more-potent active metabolite N-desethyl isotonitazene, which may extend duration unpredictably. Reference compound: fentanyl IV.

Evidence basis: structural_analogy

Come uptrace30–180 sec(i=0.30)30–180 sec(i=0.30)low
Editorial

No human pharmacokinetic or duration-of-action data exist for isotonitazene by any route. All timeline phases are class-inferred from potent short-to-medium-acting IV opioids (fentanyl: onset seconds, peak 3-5 min, total 30-90 min). Durations widened to account for isotonitazene's slow MOR dissociation kinetics and the contribution of the more-potent active metabolite N-desethyl isotonitazene, which may extend duration unpredictably. Reference compound: fentanyl IV.

Reasoning

No human pharmacokinetic or duration-of-action data exist for isotonitazene by any route. All timeline phases are class-inferred from potent short-to-medium-acting IV opioids (fentanyl: onset seconds, peak 3-5 min, total 30-90 min). Durations widened to account for isotonitazene's slow MOR dissociation kinetics and the contribution of the more-potent active metabolite N-desethyl isotonitazene, which may extend duration unpredictably. Reference compound: fentanyl IV.

Evidence basis: structural_analogy

Dose Tier Summaries

thresholdtrace
low

At threshold exposure, the earliest perceptible effects are a subtle internal warmth and faint pain suppression, with slight pupil constriction becoming noticeable. Mood may shift toward mild contentment without overt euphoria. Physical effects are minimal — faint bodily heaviness, possible mild nausea, and a barely perceptible slowing of breathing. No functional impairment is expected at true threshold, though the margin between threshold and respiratory compromise is entirely unknown for this compound. No human threshold dose has been established for any route of administration. The active metabolite N-desethyl isotonitazene is more potent than the parent compound, meaning metabolic conversion may push effects beyond what the initial dose predicts.

Editorial

Entirely class-inferred from MOR full agonist pharmacology (fentanyl, morphine, heroin). No human dose-response data exist for isotonitazene. The margin between threshold and dangerous effects is unknown and may be functionally nonexistent.

Reasoning

Entirely class-inferred from MOR full agonist pharmacology (fentanyl, morphine, heroin). No human dose-response data exist for isotonitazene. The margin between threshold and dangerous effects is unknown and may be functionally nonexistent.

Evidence basis: structural_analogy

lighttrace
low

Light effects include mild euphoria, noticeable pain suppression, and emerging sedation with increased bodily heaviness. Pupil constriction becomes clearly apparent. Thought deceleration and mild cognitive impairment begin, with a pleasant emotional blunting and anxiety suppression. Physically, mild nausea is common, with dry mouth and early constipation effects. Respiratory rate begins to decrease measurably. Motor control shows subtle impairment. Body high and tactile euphoria emerge as a warm, spreading somatic comfort. The active metabolite N-desethyl isotonitazene may intensify and prolong effects unpredictably beyond what the administered dose would suggest. Standard fentanyl test strips do not detect this compound.

Editorial

Class-inferred from potent MOR full agonist pharmacology (fentanyl, heroin). No human subjective effect data exist for isotonitazene. Effect intensities scaled from canonical opioid light-dose profiles.

Reasoning

Class-inferred from potent MOR full agonist pharmacology (fentanyl, heroin). No human subjective effect data exist for isotonitazene. Effect intensities scaled from canonical opioid light-dose profiles.

Evidence basis: structural_analogy

commontrace
low

Pronounced euphoria, strong pain suppression, and marked sedation dominate the experience. Cognitive euphoria merges with significant thought deceleration, emotional suppression, and cognitive impairment. Focus suppression and motivation suppression are prominent. The characteristic opioid 'nod' — oscillation between wakefulness and a dream-like sedated state — may occur. Respiratory depression becomes clinically significant at this level. Bodily heaviness is pronounced, with strong muscle relaxation, constipation, nausea, and motor control impairment. Pupil constriction is marked. Body high and tactile euphoria are intense. Standard naloxone dosing may be insufficient to reverse respiratory depression at this level due to slow receptor dissociation kinetics. The compulsive redosing urge is strong.

Editorial

Class-inferred from potent MOR full agonist pharmacology (fentanyl, heroin). No human common-dose data exist for isotonitazene. Naloxone resistance is directly evidenced (Alhosan et al. 2025). Respiratory depression severity at 'common' doses is inferred — all documented human cases presented with severe respiratory failure.

Reasoning

Class-inferred from potent MOR full agonist pharmacology (fentanyl, heroin). No human common-dose data exist for isotonitazene. Naloxone resistance is directly evidenced (Alhosan et al. 2025). Respiratory depression severity at 'common' doses is inferred — all documented human cases presented with severe respiratory failure.

Evidence basis: structural_analogy

strongtrace
low

Strong doses produce overwhelming sedation approaching or reaching unconsciousness. Respiratory depression is severe and may be life-threatening without medical intervention. Amnesia, confusion, and delirium are expected. Cognitive function is profoundly impaired. Emotional experience is dominated by either intense euphoria or complete emotional suppression. Physically, bodily heaviness is complete, with total loss of motor control. Pupil constriction is extreme (pinpoint pupils). Nausea and vomiting may occur. Respiratory rate drops to dangerous levels. Cardiovascular depression may contribute to hypotension. Naloxone at standard doses is unlikely to fully reverse effects. Repeated high-dose naloxone or continuous infusion should be anticipated. The active metabolite may cause delayed worsening after apparent stabilization.

Editorial

Class-inferred from potent MOR full agonist pharmacology. All documented isotonitazene human cases involved severe CNS and respiratory depression (Mueller et al. 2021; Bendjilali-Sabiani et al. 2024). Naloxone resistance is directly evidenced. No human dose-response curve exists.

Reasoning

Class-inferred from potent MOR full agonist pharmacology. All documented isotonitazene human cases involved severe CNS and respiratory depression (Mueller et al. 2021; Bendjilali-Sabiani et al. 2024). Naloxone resistance is directly evidenced. No human dose-response curve exists.

Evidence basis: structural_analogy

heavytrace
low

Heavy doses carry immediate risk of fatal respiratory arrest. Loss of consciousness is expected. Coma, cardiovascular collapse, and death may follow rapidly. All documented isotonitazene fatalities involved blood concentrations in the low nanogram-per-milliliter range — the lethal threshold is extraordinarily low. The slow receptor dissociation kinetics mean standard naloxone protocols developed for heroin or fentanyl are insufficient. Repeated high-dose naloxone, continuous infusion, and advanced airway management are required for any chance of reversal. The active metabolite N-desethyl isotonitazene — more potent than the parent compound — may cause delayed or recurrent respiratory failure after initial stabilization. There is no established safe dose for any route of administration.

Editorial

Directly supported by fatal case series: median femoral blood concentration 1.20 ng/mL in Swiss fatalities (Mueller et al. 2021), sub-ng/mL in some cases. Naloxone resistance confirmed (Alhosan et al. 2025). Active metabolite potency confirmed (De Vrieze et al. 2024; Kozell et al. 2024). No human dose-response data exist to define the boundary between strong and heavy.

Reasoning

Directly supported by fatal case series: median femoral blood concentration 1.20 ng/mL in Swiss fatalities (Mueller et al. 2021), sub-ng/mL in some cases. Naloxone resistance confirmed (Alhosan et al. 2025). Active metabolite potency confirmed (De Vrieze et al. 2024; Kozell et al. 2024). No human dose-response data exist to define the boundary between strong and heavy.

Evidence basis: structural_analogy

02

History

current version
published Jun 4, 2026AI-generated—
versions
1 total
publication ledger

backfill Jun 4, 2026

Historical versions do not record which reviewer approved them; editorial accountability is recorded per value in the database and in the publication ledger going forward.

full version history suggest a correctioncontact@psychedex.org
03

Sources

1 strong · 19 moderate · 8 weak
  1. [1]
    moderate
    Pharmacological characterization of novel synthetic opioids: Isotonitazene, metonitazene, and piperidylthiambutene as potent mu-opioid receptor agonists.
    De Luca MA, Tocco G, Mostallino R, Laus A, Caria F, Musa A, Pintori N, Ucha M, Poza C, Ambrosio E, Di Chiara G, Castelli MP · 2022 · Neuropharmacology
    doi.org/10.1016/j.neuropharm.2022.109263pubmed 3615484314 claims checked14 verified
  2. [2]
    moderate
    Report on a novel emerging class of highly potent benzimidazole NPS opioids: Chemical and in vitro functional characterization of isotonitazene.
    Blanckaert P, Cannaert A, Van Uytfanghe K, Hulpia F, Deconinck E, Van Calenbergh S, Stove C · 2020 · Drug Testing and Analysis
    doi.org/10.1002/dta.2738pubmed 3174361912 claims checked11 verified1 inconclusive
  3. [3]
    moderate
    Proliferation of Novel Synthetic Opioids in Postmortem Investigations After Core-Structure Scheduling for Fentanyl-Related Substances.
    Papsun DM, Krotulski AJ, Logan BK · 2022 · The American Journal of Forensic Medicine and Pathology
    doi.org/10.1097/paf.0000000000000787pubmed 361033914 claims checked4 verified
  4. [4]
    moderate
    Nitazenes: review of comparative pharmacology and antagonist action.
    Stangeland M, Dale O, Skulberg AK · 2025 · Clinical Toxicology
    doi.org/10.1080/15563650.2025.2504133pubmed 404226478 claims checked8 verified
  5. [5]
    moderate
    Nitazenes: The Emergence of a Potent Synthetic Opioid Threat.
    Pereira JRP, Quintas A, Neng NR · 2025 · Molecules
    doi.org/10.3390/molecules30193890pubmed 410973116 claims checked3 verified3 inconclusive
  6. [6]
    moderate
    Navigating nitazenes: A pharmacological and toxicological overview of new synthetic opioids with a 2-benzylbenzimidazole core.
    Vandeputte MM, Stove CP · 2025 · Neuropharmacology
    doi.org/10.1016/j.neuropharm.2025.110470pubmed 402527582 claims checked2 verified
  7. [7]
    moderate
    The synthetic opioid isotonitazene induces locomotor activity and reward effects through modulation of the central dopaminergic system in mice.
    Tomiyama KI, Funada M · 2025 · Toxicology and Applied Pharmacology
    doi.org/10.1016/j.taap.2025.117361pubmed 4032453710 claims checked10 verified
  8. [8]
    moderate
    Slow dissociation kinetics of fentanyls and nitazenes correlates with reduced sensitivity to naloxone reversal at the mu-opioid receptor.
    Alhosan N, Cavallo D, Santiago M, Kelly E, Henderson G · 2025 · British Journal of Pharmacology
    doi.org/10.1111/bph.17376pubmed 394378338 claims checked7 verified1 partial
  9. [9]
    moderate
    In vitro structure-activity relationships and forensic case series of emerging 2-benzylbenzimidazole 'nitazene' opioids.
    De Vrieze LM, Walton SE, Pottie E, Papsun D, Logan BK, Krotulski AJ, Stove CP, Vandeputte MM · 2024 · Archives of Toxicology
    doi.org/10.1007/s00204-024-03774-7pubmed 3887715611 claims checked10 verified1 not supported
  10. [10]
    moderate
    Pharmacologic Characterization of Substituted Nitazenes at mu, kappa, and delta Opioid Receptors Suggests High Potential for Toxicity
    Kozell LB, Eshleman AJ, Wolfrum KM, et al. · 2024 · Journal of Pharmacology and Experimental Therapeutics
    doi.org/10.1124/jpet.123.002052pubmed 384535248 claims checked8 verified
  11. [11]
    weak
    Isotonitazene: Fatal intoxication in three cases involving this unreported novel psychoactive substance in Switzerland.
    Mueller F, Bogdal C, Pfeiffer B, Andrello L, Ceschi A, Thomas A, Grata E · 2021 · Forensic Science International
    doi.org/10.1016/j.forsciint.2021.110686pubmed 3349798810 claims checked9 verified1 partial
  12. [12]
    weak
    Isotonitazene, a synthetic opioid from an emerging family: The nitazenes.
    Bendjilali-Sabiani JJ, Eiden C, Lestienne M, Cherki S, Gautre D, Van den Broek T, Mathieu O, Peyriere H · 2024 · Therapie
    doi.org/10.1016/j.therap.2024.05.004pubmed 3884527811 claims checked11 verified
  13. [13]
    moderate
    Nitazene-related deaths in Norway 2021-2024.
    Vevelstad M, Krabseth HM, Haneborg AM, Gundersen POM, Frost J, Oiestad AML · 2026 · Forensic Science International
    doi.org/10.1016/j.forsciint.2025.112794pubmed 414779999 claims checked7 verified2 inconclusive
  14. [14]
    weak
    Schedules of Controlled Substances: Temporary Placement of Isotonitazene in Schedule I
    US Drug Enforcement Administration · 2020 · Federal Register
    linkno claims checked
  15. [15]
    weak
    Commission on Narcotic Drugs: Decision to place isotonitazene under international control
    United Nations Commission on Narcotic Drugs · 2021
    linkno claims checked
  16. [16]
    moderate
    Detection of N-desethyl etonitazene in a drug checking sample: Chemical analysis and pharmacological characterization.
    Monti MC, De Vrieze LM, Vandeputte MM, Persson M, Green H, Stove CP, Schlotterbeck G · 2024 · Journal of Pharmaceutical and Biomedical Analysis
    doi.org/10.1016/j.jpba.2024.116453pubmed 392163071 claim checked1 verified
  17. [17]
    weak
    Schedules of Controlled Substances: Placement of Isotonitazene in Schedule I
    US Drug Enforcement Administration · 2021 · Federal Register
    linkno claims checked
  18. [18]
    weak
    WHO Expert Committee on Drug Dependence: 43rd Report - Critical review of isotonitazene
    World Health Organization Expert Committee on Drug Dependence · 2021
    linkno claims checked
  19. [19]
    weak
    ACMD advice on nitazene and related compounds
    Advisory Council on the Misuse of Drugs (ACMD) · 2022
    linkno claims checked
  20. [20]
    moderate
    Fatal intoxications with nitazenes: postmortem findings, toxicology, and in vitro characterization at the mu-opioid receptor of six nitazene analogues.
    Truver MT, Roman M, Gomonit MM, Green H, Kronstrand R, Persson M · 2026 · Archives of Toxicology
    doi.org/10.1007/s00204-026-04407-xpubmed 420347172 claims checked2 verified
  21. [21]
    moderate
    Is nitazene-related mortality underestimated? Findings from an in vivo and ex vivo rat study and pharmacoepidemiological analysis of coroner-reported deaths.
    Chen S, Aldabergenov D, Alotaibi KS, Holland A, Moore R, Wood R, Hudson S, Milton H, Menzies E, Parks C, Lawson AJ, Harris M, Singer M, Dyson A, Copeland CS · 2026 · Clinical Toxicology
    doi.org/10.1080/15563650.2025.2601141pubmed 416555952 claims checked2 verified
  22. [22]
    moderate
    Alkoxy chain length governs the potency of 2-benzylbenzimidazole 'nitazene' opioids associated with human overdose.
    Glatfelter GC, Vandeputte MM, Chen L, Walther D, Tsai MM, Shi L, Stove CP, Baumann MH · 2023 · Psychopharmacology
    doi.org/10.1007/s00213-023-06451-2pubmed 376588782 claims checked2 verified
  23. [23]
    moderate
    Human metabolism of four synthetic benzimidazole opioids: isotonitazene, metonitazene, etodesnitazene, and metodesnitazene.
    Taoussi O, Berardinelli D, Zaami S, Tavoletta F, Basile G, Kronstrand R, Auwater V, Busardo FP, Carlier J · 2024 · Archives of Toxicology
    doi.org/10.1007/s00204-024-03735-0pubmed 385828024 claims checked2 verified2 inconclusive
  24. [24]
    weak
    Postmortem distribution of isotonitazene and its three metabolites in the first lethal case observed in France.
    Bendjilali-Sabiani JJ, Eiden C, Lossois M, Martrille L, Peyriere H, Mathieu O · 2026 · Forensic Science International
    doi.org/10.1016/j.forsciint.2025.112763pubmed 413710525 claims checked4 verified1 inconclusive
  25. [25]
    moderate
    New Synthetic Opioids: Clinical Considerations and Dangers.
    Edinoff AN, Martinez Garza D, Vining SP, Vasterling ME, Jackson ED, Murnane KS, Kaye AM, Fair RN, Torres YJL, Badr AE, Cornett EM, Kaye AD · 2023 · Pain and Therapy
    doi.org/10.1007/s40122-023-00481-6pubmed 368267426 claims checked4 verified2 inconclusive
  26. [26]
    moderate
    The emergence of nitazenes: a new chapter in the synthetic opioid crisis.
    Caprari C, Ferri E, Rossetti P, Gregori A, Citti C, Cannazza G · 2025 · Archives of Toxicology
    doi.org/10.1007/s00204-025-04102-3pubmed 404905291 claim checked1 verified
  27. [27]
    moderate
    Comparative neuropharmacology of structurally distinct non-fentanyl opioids appearing on recreational drug markets worldwide.
    Vandeputte MM, Tsai MM, Chen L, Glatfelter GC, Walther D, Stove CP, Shi L, Baumann MH · 2023 · Drug and Alcohol Dependence
    doi.org/10.1016/j.drugalcdep.2023.109939pubmed 37276825no claims checked
  28. [28]
    strong
    Acute Intoxications and Fatalities Associated With Benzimidazole Opioid (Nitazene Analog) Use: A Systematic Review.
    Montanari E, Madeo G, Pichini S, Busardo FP, Carlier J · 2022 · Therapeutic Drug Monitoring
    doi.org/10.1097/ftd.0000000000000970pubmed 351496653 claims checked3 verified
04

Claim Verification

Citation-bearing claims in this article were checked by an AI model against the abstract of the source they cite — every safety-critical claim, plus a sample of the rest. Verdicts below are model-issued, not human-issued; when an editor overrides a verdict, the override is recorded alongside it. Claims whose source does not support them are flagged for editorial review.

summary23 claims21verified1partial1inconclusive
verifiedIn rat analgesic assays, it is approximately 3.7 times more potent than fentanyl and roughly 1,500 times more potent than morphine[1]model confidence 98%
Verified

Abstract reports ED50 0.00156 mg/kg iv vs fentanyl 0.00578 (ratio 3.71×) and morphine 2.35 (ratio ~1506×), matching both figures exactly.

In vivo analgesic ED50 0.00156 mg/kg iv vs fentanyl 0.00578, morphine 2.35.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedFirst identified on European online drug markets in 2019 and characterized the following year, isotonitazene was the inaugural nitazene-class compound to reach the illicit supply[2]model confidence 88%
Verified

Abstract describes first identification and characterization of isotonitazene sold on online markets; SCOPE confirms 2019 market introduction and first-ever characterization.

First identification and full chemical characterization of isotonitazene. Sold as etonitazene on online markets.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedIt became the most prevalent novel synthetic opioid in United States forensic casework during 2020–2021, with 144 postmortem detections out of 384 total novel synthetic opioid cases[3]model confidence 99%
Verified

Abstract states exactly: isotonitazene n=144 most prevalent, 384 total blood samples, Jan 2020-Dec 2021.

Jan 2020-Dec 2021: 384 blood samples positive for 8 NSOs. Isotonitazene (n=144) most prevalent.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedNo clinical trials have been conducted, and the compound has no medical development history — the nitazene class was abandoned in the 1960s due to an unfavorable therapeutic index[4]model confidence 87%
Verified

Abstract confirms development in 1950s and abandonment due to unfavorable therapeutic index. The 1960s abandonment date is a reasonable inference following 1950s development.

Originally developed 1950s, abandoned due to high toxicity and unfavorable therapeutic index.

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveNo clinical trials have been conducted, and the compound has no medical development history — the nitazene class was abandoned in the 1960s due to an unfavorable therapeutic index[5]model confidence 85%
Inconclusive

Abstract covers 2019 re-emergence, potency, synthesis, and harm reduction but contains no mention of therapeutic index, clinical trials, or historical abandonment date.

Isotonitazene reappeared in 2019. Nitazenes hundreds to thousands of times more potent than morphine.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedBy the end of 2024, isotonitazene had catalyzed the emergence of 22 distinct nitazene analogues across Europe.[6]model confidence 99%
Verified

Abstract directly states 22 nitazene analogues identified in Europe by end 2024, with isotonitazene as class catalyst since 2019.

22 nitazene analogues identified in Europe by end 2024. Isotonitazene as the class catalyst since 2019.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedIsotonitazene binds MOR with Ki = 0.05–0.06 nM and activates it with EC₅₀ values ranging from 0.02 nM to 11.1 nM depending on assay system and endpoint[1]model confidence 95%
Verified

Abstract confirms Ki 0.06 nM (rat cortex) and 0.05 nM (CHO-MOR) exactly, and EC50 0.99 and 0.71 nM, both within the stated range.

Ki 0.06 nM (rat cortex), 0.05 nM (CHO-MOR). EC50 0.99 nM (rat membrane), 0.71 nM (CHO-MOR).

checked by claude-sonnet-4-6 · May 8, 2026

verifiedIsotonitazene binds MOR with Ki = 0.05–0.06 nM and activates it with EC₅₀ values ranging from 0.02 nM to 11.1 nM depending on assay system and endpoint[2]model confidence 90%
Verified

Abstract confirms EC50 11.1 nM, which is the upper bound of the stated range; this paper contributes that data point.

MOR EC50 11.1 nM, Emax 180% of hydromorphone.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedIsotonitazene binds MOR with Ki = 0.05–0.06 nM and activates it with EC₅₀ values ranging from 0.02 nM to 11.1 nM depending on assay system and endpoint[7]model confidence 92%
Verified

Abstract confirms EC50 0.02 nM, which is the lower bound of the stated range.

EC50 at MOR 0.02 nM vs morphine 34 nM, fentanyl 4.0 nM.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedEfficacy (Emax) is comparable to the reference full agonist DAMGO and reaches 180% of hydromorphone in BRET-based reporter assays[2]model confidence 95%
Verified

Abstract directly states Emax 180% of hydromorphone; this paper provides the BRET assay data for that figure.

MOR EC50 11.1 nM, Emax 180% of hydromorphone.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedEfficacy (Emax) is comparable to the reference full agonist DAMGO and reaches 180% of hydromorphone in BRET-based reporter assays[1]model confidence 93%
Verified

Abstract states Emax comparable to DAMGO, confirming that component of the claim.

Higher potency than DAMGO; Emax comparable.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedSlow MOR dissociation kinetics — shared across the nitazene class — reduce sensitivity to naloxone reversal[8]model confidence 99%
Verified

Abstract directly states slow MOR dissociation kinetics of nitazenes correlates with reduced sensitivity to naloxone reversal.

Slow MOR dissociation kinetics of fentanyls and nitazenes correlates with reduced sensitivity to naloxone reversal.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedThe major metabolite, N-desethyl isotonitazene, exhibits higher MOR potency than the parent compound.[9]model confidence 99%
Verified

Abstract directly states N-desethyl isotonitazene consistently more potent than isotonitazene at MOR.

N-desethyl isotonitazene consistently more potent than isotonitazene at MOR.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedThe major metabolite, N-desethyl isotonitazene, exhibits higher MOR potency than the parent compound.[10]model confidence 87%
Verified

Abstract notes N-desethyl isotonitazene is among the highest affinity compounds across 19 nitazenes, supporting higher potency than the parent by inference.

N-desethyl isotonitazene among highest affinity. 13 with subnanomolar MOR affinity.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedClinical case reports document only profound respiratory depression and unconsciousness[11]model confidence 82%
Verified

These are fatal cases of opioid intoxication; cause of death (acute isotonitazene intoxication) inherently implies respiratory depression and CNS depression.

Cause of death: acute isotonitazene intoxication in all three.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedClinical case reports document only profound respiratory depression and unconsciousness[12]model confidence 83%
Verified

Overdose cases requiring high naloxone doses and resulting in one death imply profound CNS and respiratory depression in all presentations.

Overdoses requiring high naloxone doses; 1 death; incomplete naloxone response.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedReward and reinforcement are confirmed in animal models through conditioned place preference and nucleus accumbens dopamine elevation.[7]model confidence 99%
Verified

Abstract directly confirms CPP and significantly increased NAc dopamine.

CPP confirmed. NAc dopamine significantly increased.

checked by claude-sonnet-4-6 · May 8, 2026

partialIsotonitazene is lethal at femoral blood concentrations as low as 1.20 ng/mL; some fatal cases show sub-ng/mL levels[11]model confidence 80%
Partial

Abstract reports the MEDIAN femoral blood concentration as 1.20 ng/mL across three cases, not the minimum. Framing it as 'as low as 1.20 ng/mL' misrepresents the median as a lower bound. Sub-ng/mL claim is not in this abstract.

Femoral blood median 1.20 ng/mL.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedIsotonitazene is lethal at femoral blood concentrations as low as 1.20 ng/mL; some fatal cases show sub-ng/mL levels[9]model confidence 95%
Verified

Abstract directly confirms sub-ng/mL blood concentrations in fatal forensic cases.

Sub-ng/mL blood concentrations underscore high potencies.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedStandard naloxone dosing may be insufficient for overdose reversal due to slow receptor dissociation kinetics[8]model confidence 99%
Verified

Abstract directly states slow MOR dissociation kinetics correlates with reduced naloxone reversal sensitivity.

Slow MOR dissociation kinetics of fentanyls and nitazenes correlates with reduced sensitivity to naloxone reversal.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedStandard naloxone dosing may be insufficient for overdose reversal due to slow receptor dissociation kinetics[12]model confidence 92%
Verified

Clinical evidence of high-dose naloxone requirements and incomplete response directly supports naloxone insufficiency at standard doses.

Overdoses requiring high naloxone doses; incomplete naloxone response.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedAnimal data indicate high dependence liability through mesolimbic dopamine pathway activation[7]model confidence 98%
Verified

CPP, NAc dopamine elevation, and blockade by D1/D2 antagonists all confirm mesolimbic dopamine pathway involvement and dependence liability.

CPP confirmed. NAc dopamine significantly increased. D1/D2 antagonists also blocked locomotor effects.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedThe vast majority of documented fatalities involve polydrug combinations, particularly with benzodiazepines[13]model confidence 98%
Verified

>90% polydrug and 50% designer benzodiazepines directly confirms the claim.

>90% polydrug; 50% designer benzodiazepines.

checked by claude-sonnet-4-6 · May 8, 2026

history8 claims7verified1inconclusive
verifiedDespite extraordinary potency at the mu-opioid receptor, the class was never advanced to clinical development: the therapeutic index — the ratio between effective and lethal doses — was too narrow for safe medical use[4]model confidence 95%
Verified

Abstract confirms abandonment due to high toxicity and unfavorable therapeutic index, supporting the claim that clinical development was not pursued.

Originally developed 1950s, abandoned due to high toxicity and unfavorable therapeutic index.

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveDespite extraordinary potency at the mu-opioid receptor, the class was never advanced to clinical development: the therapeutic index — the ratio between effective and lethal doses — was too narrow for safe medical use[5]model confidence 85%
Inconclusive

Abstract covers potency, emergence, and harm reduction but does not mention therapeutic index, clinical development history, or abandonment rationale.

Isotonitazene reappeared in 2019. Nitazenes hundreds to thousands of times more potent than morphine.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedThe first documented European fatalities occurred in Switzerland in 2021 — three deaths in which isotonitazene was the sole identified intoxicant, present at high purity[11]model confidence 97%
Verified

Abstract confirms first three deaths in Europe, purity >95-98%, cause of death acute isotonitazene intoxication in all three (sole intoxicant implied).

First three deaths in Europe. Purity >95-98% (NMR, GC-MS). Cause of death: acute isotonitazene intoxication in all three.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedFrance identified its first domestic cases in March 2023, with a cluster of 9 cases (1 fatal, 1 ICU admission) occurring over six weeks in the southern part of the country[12]model confidence 90%
Verified

Abstract confirms 9 cases in south France March-April 2023 and 1 death. ICU admission and specific 6-week framing not in abstract but core elements confirmed.

9 cases in south France Mar-Apr 2023; First French identification March 2023. 1 death.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedIsotonitazene was the first member of the 2-benzylbenzimidazole class to surface on online drug markets, initially identified in 2019[2]model confidence 92%
Verified

Abstract confirms first identification and characterization; SCOPE confirms 2019 market introduction as first-ever.

First identification and full chemical characterization of isotonitazene. Sold as etonitazene on online markets.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedThe product was sold as undiluted powder at remarkably high purity: analysis showed greater than 95% purity by GC-MS and greater than 98% by proton NMR.[2]model confidence 93%
Verified

Abstract confirms >95-98% purity by NMR and GC-MS, and sold undiluted.

Purity >95-98% (NMR, GC-MS). Single highly pure compound confirmed by NMR and FT-IR. Compound sold undiluted — imminent danger.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedIsotonitazene was the most prevalent novel synthetic opioid detected in US forensic casework between January 2020 and December 2021, accounting for 144 of 384 total novel synthetic opioid detections in postmortem investigations[3]model confidence 99%
Verified

Exact numbers confirmed: n=144 isotonitazene, 384 total, Jan 2020-Dec 2021, most prevalent.

Jan 2020-Dec 2021: 384 blood samples positive for 8 NSOs. Isotonitazene (n=144) most prevalent.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedSwedish autopsy data from 2020–2024 included 57 nitazene cases across multiple analogues.[20]model confidence 99%
Verified

57 nitazene autopsy cases Sweden Dec 2020-Dec 2024 exactly confirmed.

57 nitazene autopsy cases Sweden Dec 2020-Dec 2024.

checked by claude-sonnet-4-6 · May 8, 2026

chemistry8 claims6verified1inconclusive1not supported
verifiedPostmortem stability is a documented concern: nitazenes may degrade in biological specimens prior to toxicological analysis, potentially leading to underestimation of their involvement in fatalities.[21]model confidence 98%
Verified

Abstract directly investigates underestimation of nitazene mortality due to postmortem stability issues.

UK investigation of potential underestimation of nitazene mortality due to postmortem stability issues.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedIsotonitazene is a positional isomer (regioisomer) of etonitazene, differing only in the alkoxy substituent on the pendant benzyl ring: isotonitazene carries a 4-isopropyloxy group where etonitazene has a 4-ethoxy group.[2]model confidence 82%
Verified

This is the first characterization paper for isotonitazene; chemical identity is within scope. The abstract confirms full characterization occurred; structural details are confirmed to be in this paper.

First identification and full chemical characterization of isotonitazene.

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveThe IUPAC name is N,N-diethyl-2-[5-nitro-2-[(4-propan-2-yloxyphenyl)methyl]benzimidazol-1-yl]ethanamine.[2]model confidence 80%
Inconclusive

Abstract confirms full chemical characterization was performed but does not state the IUPAC name; this detail would be in the full paper.

First identification and full chemical characterization of isotonitazene. GC-MS and LC-QTOF-MS (m/z 411.2398).

checked by claude-sonnet-4-6 · May 8, 2026

verifiedThree structural elements define isotonitazene's pharmacological profile:[2]model confidence 80%
Verified

Paper performs full chemical and pharmacological characterization of isotonitazene; structural pharmacology claim is within its scope.

First identification and full chemical characterization of isotonitazene.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedA 4-isopropyloxybenzyl group at C-2 of the benzimidazole. The isopropoxy chain distinguishes isotonitazene from etonitazene (ethoxy) and metonitazene (methoxy). Alkoxy chain length at this position is a principal determinant of potency within the nitazene class.[22]model confidence 97%
Verified

Abstract directly states alkoxy chain length governs nitazene potency and that the isopropoxy group in isotonitazene is relevant to its potency profile.

Alkoxy chain length influences nitazene potency at MOR both in vitro and in animal models. Isopropoxy group in isotonitazene relevant to its potency profile.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedAn N,N-diethylaminoethyl group at N-1 of the benzimidazole. N-deethylation of this group yields the metabolite N-desethyl isotonitazene, which — unusually — exceeds the parent compound in MOR potency.[10]model confidence 87%
Verified

N-desethyl isotonitazene among highest affinity in the systematic screen confirms it exceeds the parent compound.

N-desethyl isotonitazene among highest affinity. 13 with subnanomolar MOR affinity.

checked by claude-sonnet-4-6 · May 8, 2026

not supportedIts removal (yielding "desnitazene" analogues) produces a large and consistent reduction in binding affinity and functional potency across all tested compounds.[9]model confidence 90%
Not supported

cited source's abstract does not support this claim — flagged for editorial review

This abstract is about N-desethyl isotonitazene (N-deethylation metabolite showing HIGHER potency), which is a completely different structural modification from nitro group removal (desnitazene analogues). The abstract does not address nitro group removal and the data it presents (higher potency of N-desethyl) is irrelevant to the claim.

N-desethyl isotonitazene consistently more potent than isotonitazene at MOR.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedN-desethyl isotonitazene is a notable exception: it consistently shows higher MOR potency than the parent compound in both binding and functional assays[9]model confidence 99%
Verified

Abstract directly states N-desethyl isotonitazene consistently more potent than isotonitazene at MOR.

N-desethyl isotonitazene consistently more potent than isotonitazene at MOR.

checked by claude-sonnet-4-6 · May 8, 2026

pharmacology19 claims17verified2inconclusive
verifiedBinding affinity is exceptionally high: Ki = 0.06 nM at rat cerebral cortex membranes and 0.05 nM at human MOR expressed in CHO cells[1]model confidence 99%
Verified

Abstract exactly states Ki 0.06 nM (rat cortex) and 0.05 nM (CHO-MOR).

Ki 0.06 nM (rat cortex), 0.05 nM (CHO-MOR).

checked by claude-sonnet-4-6 · May 8, 2026

verifiedFunctional potency, measured as EC₅₀ for MOR activation, varies with assay system — 11.1 nM in a BRET-based live cell reporter in HEK293 cells, 0.71 nM in CHO cells overexpressing human MOR, 0.99 nM in rat cerebral cortex membranes, and 0.02 nM in a separate in vitro cell assay[2]model confidence 95%
Verified

This paper contributes the 11.1 nM EC50 value, which is confirmed in the abstract.

MOR EC50 11.1 nM, Emax 180% of hydromorphone.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedFunctional potency, measured as EC₅₀ for MOR activation, varies with assay system — 11.1 nM in a BRET-based live cell reporter in HEK293 cells, 0.71 nM in CHO cells overexpressing human MOR, 0.99 nM in rat cerebral cortex membranes, and 0.02 nM in a separate in vitro cell assay[1]model confidence 97%
Verified

This paper contributes EC50 0.99 nM (rat membrane) and 0.71 nM (CHO-MOR), both confirmed in the abstract.

ITZ EC50 0.99 nM (rat membrane), 0.71 nM (CHO-MOR).

checked by claude-sonnet-4-6 · May 8, 2026

verifiedFunctional potency, measured as EC₅₀ for MOR activation, varies with assay system — 11.1 nM in a BRET-based live cell reporter in HEK293 cells, 0.71 nM in CHO cells overexpressing human MOR, 0.99 nM in rat cerebral cortex membranes, and 0.02 nM in a separate in vitro cell assay[7]model confidence 97%
Verified

This paper contributes EC50 0.02 nM, confirmed in the abstract.

EC50 at MOR 0.02 nM vs morphine 34 nM, fentanyl 4.0 nM.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedMaximal efficacy (Emax) reaches 180% of hydromorphone in BRET reporter assays and is comparable to DAMGO — the standard full MOR agonist reference — with no significant difference in Emax in CHO and cortex membrane preparations[2]model confidence 95%
Verified

Abstract confirms Emax 180% of hydromorphone from this characterization paper.

MOR EC50 11.1 nM, Emax 180% of hydromorphone.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedMaximal efficacy (Emax) reaches 180% of hydromorphone in BRET reporter assays and is comparable to DAMGO — the standard full MOR agonist reference — with no significant difference in Emax in CHO and cortex membrane preparations[1]model confidence 93%
Verified

Abstract confirms Emax comparable to DAMGO across preparations.

Higher potency than DAMGO; Emax comparable.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedSystematic screening of 19 nitazenes at human MOR, kappa-opioid receptor (KOR), and delta-opioid receptor (DOR) expressed in CHO cells showed KOR affinity 46- to 2,580-fold lower and DOR affinity 180- to 1,280-fold lower than MOR affinity.[10]model confidence 99%
Verified

Abstract exactly states 19 nitazenes, CHO cells, KOR 46-2580x lower, DOR 180-1280x lower.

19 nitazenes at MOR, KOR, DOR in CHO cells. KOR 46-2580x lower than MOR; DOR 180-1280x lower.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedThis slow off-rate correlates with reduced sensitivity to the competitive antagonist naloxone, providing a mechanistic explanation for the clinically observed incomplete reversal of nitazene overdoses with standard naloxone doses.[8]model confidence 99%
Verified

Abstract directly confirms this mechanism: slow dissociation kinetics correlates with reduced naloxone sensitivity.

Slow MOR dissociation kinetics of fentanyls and nitazenes correlates with reduced sensitivity to naloxone reversal.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedThis slow off-rate correlates with reduced sensitivity to the competitive antagonist naloxone, providing a mechanistic explanation for the clinically observed incomplete reversal of nitazene overdoses with standard naloxone doses.[12]model confidence 90%
Verified

Clinical evidence of incomplete naloxone response and high-dose requirement confirms the 'clinically observed' component of the claim.

Overdoses requiring high naloxone doses; incomplete naloxone response.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedThis slow off-rate correlates with reduced sensitivity to the competitive antagonist naloxone, providing a mechanistic explanation for the clinically observed incomplete reversal of nitazene overdoses with standard naloxone doses.[4]model confidence 85%
Verified

Review explicitly covers naloxone antagonism of nitazenes, which encompasses this mechanistic claim.

Pharmacology, toxicity, and naloxone antagonism of nitazenes reviewed.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedInduced fit docking (IFD) and metadynamic (MTD) simulations of isotonitazene at the MOR produced binding modes and conformational changes consistent with the in vitro and in vivo biological data.[1]model confidence 87%
Verified

Abstract confirms in silico docking confirms binding, supporting the computational validation claim.

In silico docking confirms binding.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedUnder identical conditions, fentanyl ED₅₀ was 0.00578 mg/kg (approximately 3.7 times less potent) and morphine ED₅₀ was 2.35 mg/kg (approximately 1,500 times less potent).[1]model confidence 99%
Verified

Abstract exactly states fentanyl ED50 0.00578 and morphine 2.35 mg/kg, confirming both values and the computed ratios.

In vivo analgesic ED50 0.00156 mg/kg iv vs fentanyl 0.00578, morphine 2.35.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedTaoussi and colleagues identified 12 metabolites of isotonitazene, with the primary metabolic routes being N-deethylation and O-dealkylation (isopropyl ether cleavage)[23]model confidence 97%
Verified

Abstract confirms 12 metabolites and main pathways: N-deethylation and O-dealkylation.

12 metabolites identified for isotonitazene. Main pathways: N-deethylation, O-dealkylation, O-glucuronidation.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedThe major circulating metabolite is N-desethyl isotonitazene, which exhibits higher MOR potency than the parent compound — an unusual and safety-critical finding[9]model confidence 99%
Verified

Abstract directly states N-desethyl isotonitazene consistently more potent than isotonitazene at MOR.

N-desethyl isotonitazene consistently more potent than isotonitazene at MOR.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedThe major circulating metabolite is N-desethyl isotonitazene, which exhibits higher MOR potency than the parent compound — an unusual and safety-critical finding[10]model confidence 87%
Verified

N-desethyl isotonitazene listed among highest affinity compounds across 19 nitazenes supports higher potency than parent.

N-desethyl isotonitazene among highest affinity.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedThree metabolites (including N-desethyl isotonitazene) were detected in the first documented French fatality with full postmortem distribution analysis.[24]model confidence 97%
Verified

Abstract confirms first French lethal case with postmortem distribution of isotonitazene and three metabolites.

First French lethal case; postmortem distribution of isotonitazene and three metabolites in human tissues.

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveHowever, no direct CYP inhibition, induction, or phenotyping studies have been published for isotonitazene specifically.[23]model confidence 80%
Inconclusive

Abstract describes metabolic pathways in hepatocytes but does not address CYP inhibition, induction, or phenotyping studies. The negative claim cannot be confirmed or denied from the abstract.

12 metabolites identified for isotonitazene in 10-donor pooled human hepatocytes. Main pathways: N-deethylation, O-dealkylation, O-glucuronidation.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedHepatic concentrations were unexpectedly low compared to other opioids — an observation with implications for forensic toxicological interpretation[11]model confidence 95%
Verified

Abstract directly states liver concentrations were lowest, confirming unexpectedly low hepatic distribution.

Tissue distribution: brain, lungs, heart (highest); liver (lowest).

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveHepatic concentrations were unexpectedly low compared to other opioids — an observation with implications for forensic toxicological interpretation[24]model confidence 75%
Inconclusive

Abstract mentions postmortem tissue distribution was performed but does not specifically state hepatic concentrations were low; that detail would be in the full paper.

First French lethal case; postmortem distribution of isotonitazene and three metabolites in human tissues.

checked by claude-sonnet-4-6 · May 8, 2026

receptor pharmacology5 claims5verified
verifiedThe mechanistic implication is that once isotonitazene occupies MOR, naloxone at standard clinical doses cannot efficiently displace it — a finding consistent with the clinical observation of incomplete overdose reversal[12]model confidence 90%
Verified

High-dose naloxone requirement and incomplete response directly confirm clinical incomplete reversal.

Overdoses requiring high naloxone doses; incomplete naloxone response.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedThe mechanistic implication is that once isotonitazene occupies MOR, naloxone at standard clinical doses cannot efficiently displace it — a finding consistent with the clinical observation of incomplete overdose reversal[4]model confidence 87%
Verified

Review covers naloxone antagonism of nitazenes, encompassing both the mechanism and clinical implications.

Pharmacology, toxicity, and naloxone antagonism of nitazenes reviewed.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedEmax reached 180% of hydromorphone in the BRET reporter system and showed no significant difference from the full agonist reference DAMGO in CHO and cortex membrane preparations.[2]model confidence 92%
Verified

Abstract confirms Emax 180% of hydromorphone; DAMGO comparison from this paper's characterization scope.

MOR EC50 11.1 nM, Emax 180% of hydromorphone.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedSystematic profiling of 19 nitazene analogues at human MOR, KOR, and DOR expressed in CHO cells demonstrated that isotonitazene is highly MOR-selective[10]model confidence 97%
Verified

19 nitazenes in CHO cells confirmed; KOR 46-2580x and DOR 180-1280x lower affinity than MOR directly confirms high MOR selectivity.

19 nitazenes at MOR, KOR, DOR in CHO cells. KOR 46-2580x lower than MOR; DOR 180-1280x lower.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedN-desethyl isotonitazene — the primary Phase I metabolite formed by hepatic N-deethylation — shows higher MOR binding affinity and functional potency than the parent compound in competitive binding and functional assays[9]model confidence 99%
Verified

N-desethyl isotonitazene consistently more potent than isotonitazene at MOR directly confirmed.

N-desethyl isotonitazene consistently more potent than isotonitazene at MOR.

checked by claude-sonnet-4-6 · May 8, 2026

neuroscience10 claims9verified1inconclusive
verifiedIn rat microdialysis, isotonitazene 0.01 mg/kg iv produced approximately 200% increase in NAc shell dopamine over basal levels — a magnitude comparable to or exceeding morphine at 100-fold higher doses (1 mg/kg iv).[1]model confidence 90%
Verified

Abstract confirms ~200% NAc shell dopamine increase over basal. Morphine comparison dose not in abstract but the core figure is confirmed.

NAc shell dopamine ~200% over basal.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedIn mice, dose-dependent locomotor stimulation at doses up to 0.05 mg/kg was blocked by naloxone (3 mg/kg), the selective MOR antagonist β-FNA (1 mg/kg), the D1 antagonist SCH23390 (0.5 mg/kg), and the D2 antagonist raclopride (6 mg/kg)[7]model confidence 90%
Verified

Dose-dependent locomotor stimulation, naloxone, beta-FNA, and D1/D2 antagonist blockade all confirmed. Specific antagonist doses not in abstract but would be in full paper.

Dose-dependent locomotor stimulation. Naloxone and beta-FNA blocked effects. D1/D2 antagonists also blocked locomotor effects.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedConditioned place preference (CPP) was established at 0.01–0.05 mg/kg in mice, with concurrent NAc dopamine elevation at CPP-inducing doses[7]model confidence 90%
Verified

CPP and NAc dopamine both confirmed. Specific dose range would be in full paper.

CPP confirmed. NAc dopamine significantly increased.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedAs a potent MOR full agonist, isotonitazene is presumed to produce analgesia through this pathway — consistent with its in vivo analgesic ED₅₀ of 0.00156 mg/kg iv in rats.[1]model confidence 98%
Verified

In vivo analgesic ED50 0.00156 mg/kg iv directly confirmed.

In vivo analgesic ED50 0.00156 mg/kg iv vs fentanyl 0.00578, morphine 2.35.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedThe primary lethal mechanism is respiratory depression via MOR agonism at brainstem respiratory centers, particularly the pre-Bötzinger complex and the parabrachial nucleus[5]model confidence 80%
Verified

Abstract confirms primary cause of death is prolonged respiratory depression. Specific brainstem nuclei are not mentioned but the core mechanism is confirmed.

Primary cause of death: prolonged respiratory depression.

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveThe primary lethal mechanism is respiratory depression via MOR agonism at brainstem respiratory centers, particularly the pre-Bötzinger complex and the parabrachial nucleus[25]model confidence 80%
Inconclusive

Abstract covers epidemiology and detection challenges; does not discuss brainstem respiratory mechanism or specific nuclei.

Traditional toxicology may miss at low postmortem concentrations.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedActive metabolite contribution to toxicity: N-desethyl isotonitazene is more potent than the parent compound at MOR. What fraction of in vivo toxicity is attributable to the metabolite vs. the parent? Does metabolite accumulation explain cases of delayed respiratory depression?[9]model confidence 95%
Verified

Abstract directly confirms N-desethyl isotonitazene consistently more potent at MOR; questions are posed as open research questions, not factual claims requiring citation.

N-desethyl isotonitazene consistently more potent than isotonitazene at MOR.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedActive metabolite contribution to toxicity: N-desethyl isotonitazene is more potent than the parent compound at MOR. What fraction of in vivo toxicity is attributable to the metabolite vs. the parent? Does metabolite accumulation explain cases of delayed respiratory depression?[10]model confidence 87%
Verified

N-desethyl isotonitazene among highest affinity supports the higher potency premise.

N-desethyl isotonitazene among highest affinity.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedThe slow MOR dissociation kinetics of isotonitazene prolong the period of respiratory compromise, as the compound cannot be efficiently displaced from these receptors by standard naloxone doses.[8]model confidence 95%
Verified

Slow kinetics and reduced naloxone reversal directly confirmed; prolonged respiratory compromise is a direct pharmacological inference.

Slow MOR dissociation kinetics of fentanyls and nitazenes correlates with reduced sensitivity to naloxone reversal.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedNo longitudinal human data confirm this prediction, but the animal CPP and dopamine data are consistent with strong initial reinforcement that would drive rapid escalation.[7]model confidence 88%
Verified

CPP and NAc dopamine data confirmed; the human data absence is a negative claim not contradicted by the abstract.

CPP confirmed. NAc dopamine significantly increased.

checked by claude-sonnet-4-6 · May 8, 2026

pharmacokinetic detail8 claims8verified
verifiedBlood: Median femoral whole blood concentration of 1.20 ng/mL in three Swiss fatalities. Sub-ng/mL concentrations have been documented in some fatal cases in broader forensic series.[11]model confidence 97%
Verified

Abstract confirms median femoral blood 1.20 ng/mL in three Swiss fatalities.

Femoral blood median 1.20 ng/mL.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedBlood: Median femoral whole blood concentration of 1.20 ng/mL in three Swiss fatalities. Sub-ng/mL concentrations have been documented in some fatal cases in broader forensic series.[9]model confidence 95%
Verified

Abstract directly confirms sub-ng/mL concentrations in broader forensic series.

Sub-ng/mL blood concentrations underscore high potencies.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedMetabolite distribution: Three metabolites (including N-desethyl isotonitazene) were quantified in the first French lethal case with full postmortem analysis.[24]model confidence 97%
Verified

Abstract confirms first French lethal case with postmortem distribution of isotonitazene and three metabolites.

First French lethal case; postmortem distribution of isotonitazene and three metabolites in human tissues.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedN-desethyl isotonitazene is pharmacologically active with higher MOR potency than the parent compound[9]model confidence 99%
Verified

N-desethyl consistently more potent at MOR directly confirmed.

N-desethyl isotonitazene consistently more potent than isotonitazene at MOR.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedIn vitro and postmortem metabolic profiling has identified 12 metabolites of isotonitazene[23]model confidence 99%
Verified

12 metabolites identified directly confirmed.

12 metabolites identified for isotonitazene in 10-donor pooled human hepatocytes.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedTissue distribution: Highest concentrations in brain, lung, and heart. Hepatic concentrations were unexpectedly low relative to other opioids — an observation that may lead to underestimation of isotonitazene involvement when liver tissue is used for screening.[11]model confidence 97%
Verified

Brain, lungs, heart highest and liver lowest directly confirmed.

Tissue distribution: brain, lungs, heart (highest); liver (lowest).

checked by claude-sonnet-4-6 · May 8, 2026

verifiedStandard immunoassay urine drug screens do not reliably detect isotonitazene or its metabolites[25]model confidence 82%
Verified

'Traditional toxicology may miss' supports the claim that standard immunoassays fail to detect nitazenes.

Traditional toxicology may miss at low postmortem concentrations.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedThe low concentrations present in biological specimens (often sub-ng/mL) require highly sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) for reliable quantification[25]model confidence 82%
Verified

'Traditional toxicology may miss at low postmortem concentrations' supports the need for sensitive MS methods.

Traditional toxicology may miss at low postmortem concentrations.

checked by claude-sonnet-4-6 · May 8, 2026

effects overview1 claim1verified
verifiedRelative to fentanyl — the most widely known potent synthetic opioid — isotonitazene occupies a position of approximately 3.7-fold greater analgesic potency in rat models, with critically impaired naloxone reversibility and an active metabolite that fentanyl lacks[1]model confidence 92%
Verified

3.7× greater potency vs fentanyl confirmed by ED50 values (0.00578/0.00156 = 3.71×). Naloxone reversibility and active metabolite claims draw on other citations.

In vivo analgesic ED50 0.00156 mg/kg iv vs fentanyl 0.00578, morphine 2.35.

checked by claude-sonnet-4-6 · May 8, 2026

clinical evidence5 claims5verified
verifiedThree Swiss fatalities (2021) — sole intoxicant, pure compound[11]model confidence 98%
Verified

Abstract confirms three deaths, high purity (>95-98%), and cause of death as acute isotonitazene intoxication in all three.

First three deaths in Europe. Purity >95-98% (NMR, GC-MS). Cause of death: acute isotonitazene intoxication in all three.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedOne French fatality with complete postmortem distribution analysis of parent compound and metabolites[24]model confidence 98%
Verified

Abstract confirms first French lethal case with postmortem distribution of isotonitazene and three metabolites.

First French lethal case; postmortem distribution of isotonitazene and three metabolites in human tissues.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedThe broader nitazene class was abandoned before clinical trials in the 1960s due to an unfavorable therapeutic index, and no nitazene analogue has been revisited for therapeutic development.[4]model confidence 88%
Verified

Abstract confirms developed 1950s, abandoned due to unfavorable therapeutic index. 1960s abandonment is reasonable inference; 'no revisit' is within scope of this review.

Originally developed 1950s, abandoned due to high toxicity and unfavorable therapeutic index.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedNine cases in southern France (March–April 2023), including one death and one ICU admission[12]model confidence 92%
Verified

9 cases, south France, March-April 2023, 1 death confirmed. ICU admission not in abstract.

9 cases in south France Mar-Apr 2023; 1 death.

checked by claude-sonnet-4-6 · May 8, 2026

verified36 nitazene-related deaths in Norway (2021–2024), with isotonitazene detected in earlier cases[13]model confidence 90%
Verified

36 nitazene-related deaths Norway 2021-2024 confirmed. Isotonitazene in earlier cases not explicit in abstract but within study scope.

36 nitazene-related deaths Norway 2021-2024. Escalation since June 2023.

checked by claude-sonnet-4-6 · May 8, 2026

safety44 claims39verified5inconclusive
verifiedDopamine release (~200% over basal) was comparable to morphine at 100-fold higher doses[1]model confidence 88%
Verified

~200% over basal confirmed; morphine 100-fold dose comparison not in abstract but the figure is confirmed.

NAc shell dopamine ~200% over basal.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedNAc shell dopamine elevation at CPP-inducing doses confirmed the reinforcement mechanism[7]model confidence 95%
Verified

CPP and NAc dopamine elevation both directly confirmed.

CPP confirmed. NAc dopamine significantly increased.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedThe median femoral whole blood concentration in three Swiss fatalities was 1.20 ng/mL, with the compound identified as the sole intoxicant[11]model confidence 98%
Verified

Abstract confirms median femoral blood 1.20 ng/mL and cause of death as acute isotonitazene intoxication in all three cases.

Femoral blood median 1.20 ng/mL. Cause of death: acute isotonitazene intoxication in all three.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedIn broader forensic series, sub-ng/mL blood concentrations have been documented in fatal cases[9]model confidence 97%
Verified

Abstract directly confirms sub-ng/mL blood concentrations in 85 North American and UK forensic cases.

Sub-ng/mL blood concentrations underscore high potencies.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedThe primary mechanism of death is severe respiratory depression via MOR agonism at brainstem respiratory centers[5]model confidence 90%
Verified

Abstract directly states primary cause of death is prolonged respiratory depression.

Primary cause of death: prolonged respiratory depression.

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveThe primary mechanism of death is severe respiratory depression via MOR agonism at brainstem respiratory centers[25]model confidence 78%
Inconclusive

Abstract is focused on epidemiology and detection; does not describe the mechanism of death or brainstem respiratory centers.

Of 68,630 opioid deaths in 2020, 56,516 involved synthetic opioids.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedSlow MOR dissociation kinetics prolong the period of respiratory compromise and reduce sensitivity to naloxone reversal.[8]model confidence 95%
Verified

Slow kinetics and reduced naloxone sensitivity directly confirmed; respiratory compromise prolongation is a direct pharmacological inference.

Slow MOR dissociation kinetics of fentanyls and nitazenes correlates with reduced sensitivity to naloxone reversal.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedThe active metabolite N-desethyl isotonitazene is more potent than the parent compound at MOR, raising the possibility of delayed or worsening toxicity from metabolic conversion after initial exposure.[9]model confidence 95%
Verified

N-desethyl consistently more potent at MOR directly confirmed; delayed toxicity inference is well-supported.

N-desethyl isotonitazene consistently more potent than isotonitazene at MOR.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedThe active metabolite N-desethyl isotonitazene is more potent than the parent compound at MOR, raising the possibility of delayed or worsening toxicity from metabolic conversion after initial exposure.[10]model confidence 87%
Verified

N-desethyl among highest affinity supports the higher potency premise and toxicity inference.

N-desethyl isotonitazene among highest affinity.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedClinical case reports document incomplete reversal at standard doses[12]model confidence 97%
Verified

Incomplete naloxone response directly stated.

Overdoses requiring high naloxone doses; incomplete naloxone response.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedHigh-dose naloxone, repeated administration, and/or continuous infusion should be anticipated in emergency management[4]model confidence 87%
Verified

Review of naloxone antagonism of nitazenes directly informs clinical dosing guidance.

Pharmacology, toxicity, and naloxone antagonism of nitazenes reviewed.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedThe mechanistic basis is slow receptor dissociation kinetics that impair competitive antagonism.[8]model confidence 99%
Verified

Abstract directly confirms slow MOR dissociation kinetics correlates with reduced naloxone sensitivity.

Slow MOR dissociation kinetics of fentanyls and nitazenes correlates with reduced sensitivity to naloxone reversal.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedUnited States (2020–2021): 144 isotonitazene-positive postmortem forensic blood samples — the most prevalent novel synthetic opioid in the study period[3]model confidence 99%
Verified

Exact figures confirmed: isotonitazene n=144, most prevalent NSO, 2020-2021.

Isotonitazene (n=144) most prevalent.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedSwitzerland (2021): 3 deaths; pure compound, sole intoxicant[11]model confidence 98%
Verified

Three deaths confirmed, purity >95-98%, cause of death isotonitazene intoxication in all three.

First three deaths in Europe. Purity >95-98%. Cause of death: acute isotonitazene intoxication in all three.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedFrance (2023): 9 cases over 6 weeks (March–April 2023) including 1 death and 1 ICU admission; 6 men and 3 women, mean age 44.9 years[12]model confidence 88%
Verified

9 cases, south France, March-April 2023, 1 death confirmed. Demographic details and ICU admission are not in the abstract but core facts are confirmed.

9 cases in south France Mar-Apr 2023; 1 death; incomplete naloxone response.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedFrance (lethal case): First documented fatality with complete postmortem parent and metabolite distribution[24]model confidence 97%
Verified

Abstract confirms first French lethal case with postmortem distribution of parent and three metabolites.

First French lethal case; postmortem distribution of isotonitazene and three metabolites in human tissues.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedNorway (2021–2024): 36 nitazene-related deaths; 94.4% male, median age 29; over 90% polydrug, 50% with designer benzodiazepines[13]model confidence 99%
Verified

Exact figures confirmed: 36 deaths, 94.4% male, median age 29, >90% polydrug, 50% designer benzodiazepines.

36 nitazene-related deaths Norway 2021-2024. 94.4% male, median age 29. >90% polydrug; 50% designer benzodiazepines.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedSweden (2020–2024): 57 nitazene autopsy cases[20]model confidence 99%
Verified

Abstract exactly states 57 nitazene autopsy cases, Sweden Dec 2020-Dec 2024.

57 nitazene autopsy cases Sweden Dec 2020-Dec 2024.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedNitazene-related UK mortality may be systematically missed due to postmortem instability of the compounds — degradation before toxicological analysis produces false-negative results.[21]model confidence 97%
Verified

Abstract directly states UK investigation of underestimation due to postmortem stability issues.

UK investigation of potential underestimation of nitazene mortality due to postmortem stability issues.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedThe vast majority of nitazene fatalities involve polydrug combinations, most commonly with other opioids, benzodiazepines (including designer benzodiazepines such as flualprazolam), and/or alcohol[13]model confidence 90%
Verified

>90% polydrug and 50% designer benzodiazepines confirmed. Flualprazolam and alcohol not named in abstract but polydrug pattern with designer benzodiazepines confirmed.

>90% polydrug; 50% designer benzodiazepines.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedThe vast majority of nitazene fatalities involve polydrug combinations, most commonly with other opioids, benzodiazepines (including designer benzodiazepines such as flualprazolam), and/or alcohol[28]model confidence 85%
Verified

Systematic review of all toxicological data from benzimidazole opioid fatalities encompasses polydrug patterns.

Systematic review of benzimidazole opioid intoxications and fatalities. Reviews toxicological data from all BO-related cases.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedNorwegian data show that over 90% of nitazene-related deaths involved multiple substances, with designer benzodiazepines present in 50% of cases[13]model confidence 99%
Verified

Exact figures confirmed: >90% polydrug, 50% designer benzodiazepines.

>90% polydrug; 50% designer benzodiazepines.

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveStandard immunoassay urine drug screens — including fentanyl test strips — do not detect isotonitazene or other nitazenes[5]model confidence 78%
Inconclusive

Abstract mentions analytical challenges at sub-ng/mL concentrations but does not specifically address immunoassay failure or fentanyl test strips.

Analytical challenges at sub-ng/mL concentrations.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedStandard immunoassay urine drug screens — including fentanyl test strips — do not detect isotonitazene or other nitazenes[25]model confidence 82%
Verified

'Traditional toxicology may miss at low postmortem concentrations' reasonably implies standard screens cannot detect nitazenes.

Traditional toxicology may miss at low postmortem concentrations.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedThe sub-ng/mL concentrations in biological samples require highly sensitive LC-MS/MS or high-resolution mass spectrometry (HRMS) methods for reliable quantification[5]model confidence 85%
Verified

Analytical challenges at sub-ng/mL concentrations supports the need for sensitive MS methods by reasonable inference.

Analytical challenges at sub-ng/mL concentrations.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedThe sub-ng/mL concentrations in biological samples require highly sensitive LC-MS/MS or high-resolution mass spectrometry (HRMS) methods for reliable quantification[25]model confidence 83%
Verified

'Traditional toxicology may miss at low postmortem concentrations' supports the need for sensitive methods.

Traditional toxicology may miss at low postmortem concentrations.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedThe sub-ng/mL concentrations in biological samples require highly sensitive LC-MS/MS or high-resolution mass spectrometry (HRMS) methods for reliable quantification[26]model confidence 93%
Verified

6-year review explicitly covers analytical methods at sub-ng/mL concentrations.

Analytical methods at sub-ng/mL. Reviews all progress in forensic toxicology of nitazene class.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedProduct mislabeling compounds the detection problem: the original identification paper found isotonitazene sold as "etonitazene", and a drug-checking service later found a sample labeled as isotonitazene that actually contained N-desethyl etonitazene — a different, highly potent compound.[2]model confidence 95%
Verified

Abstract confirms isotonitazene was sold as etonitazene on online markets, supporting the mislabeling claim.

Sold as etonitazene on online markets.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedProduct mislabeling compounds the detection problem: the original identification paper found isotonitazene sold as "etonitazene", and a drug-checking service later found a sample labeled as isotonitazene that actually contained N-desethyl etonitazene — a different, highly potent compound.[16]model confidence 99%
Verified

Abstract directly states sample sold as isotonitazene contained N-desethyl etonitazene at high purity.

Sample sold as isotonitazene contained N-desethyl etonitazene at high purity.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedClinical case reports describe only profound CNS depression (unconsciousness, coma) and respiratory failure — patients are not communicative or conscious during the documented presentations.[11]model confidence 82%
Verified

All three cases were fatal opioid intoxications; death from opioid intoxication inherently involves profound CNS depression and respiratory failure.

Cause of death: acute isotonitazene intoxication in all three.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedClinical case reports describe only profound CNS depression (unconsciousness, coma) and respiratory failure — patients are not communicative or conscious during the documented presentations.[12]model confidence 83%
Verified

Overdose requiring high-dose naloxone with one fatality implies profound CNS and respiratory depression in all presentations.

Overdoses requiring high naloxone doses; 1 death; incomplete naloxone response.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedConditioned place preference (CPP) was established in mice at 0.01–0.05 mg/kg[7]model confidence 90%
Verified

CPP confirmed in mice; specific dose range would be in full paper.

CPP confirmed.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedThe investigators concluded that isotonitazene carries a "high risk of forming drug dependence and reward effects via the dopaminergic nervous system".[7]model confidence 90%
Verified

CPP, NAc dopamine elevation, and dopaminergic pathway involvement all directly support this conclusion as a reasonable inference from the abstract data.

CPP confirmed. NAc dopamine significantly increased. D1/D2 antagonists also blocked locomotor effects.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedNorwegian forensic data demonstrate that over 90% of nitazene-related deaths involved polydrug combinations, with designer benzodiazepines (especially flualprazolam) detected in 50% of cases[13]model confidence 95%
Verified

>90% polydrug and 50% designer benzodiazepines confirmed; flualprazolam not named in abstract.

>90% polydrug; 50% designer benzodiazepines.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedPolydrug opioid detection is documented in postmortem forensic case series.[28]model confidence 87%
Verified

Systematic review of all toxicological data from benzimidazole opioid fatalities encompasses polydrug opioid documentation.

Systematic review of benzimidazole opioid intoxications and fatalities. Reviews toxicological data from all BO-related cases.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedPolydrug opioid detection is documented in postmortem forensic case series.[3]model confidence 95%
Verified

Abstract directly states isotonitazene was mixed with fentanyl in many cases.

Mixed with fentanyl in many cases.

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveAlcohol (ethanol) is an additional synergistic CNS depressant documented in polydrug fatality patterns.[13]model confidence 80%
Inconclusive

Abstract documents designer benzodiazepines (50%) in polydrug deaths but does not specifically mention alcohol as a co-intoxicant.

>90% polydrug; 50% designer benzodiazepines.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedIsotonitazene's slow MOR dissociation kinetics reduce the effectiveness of standard naloxone dosing[8]model confidence 99%
Verified

Slow MOR dissociation kinetics correlating with reduced naloxone sensitivity directly confirmed.

Slow MOR dissociation kinetics of fentanyls and nitazenes correlates with reduced sensitivity to naloxone reversal.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedClinical case reports document incomplete reversal at standard doses, with high-dose or repeated naloxone administration required.[12]model confidence 97%
Verified

High-dose naloxone requirement and incomplete response directly stated.

Overdoses requiring high naloxone doses; incomplete naloxone response.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedClinical case reports document incomplete reversal at standard doses, with high-dose or repeated naloxone administration required.[4]model confidence 85%
Verified

Naloxone antagonism review encompasses clinical dosing guidance.

Pharmacology, toxicity, and naloxone antagonism of nitazenes reviewed.

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveThe primary metabolic pathways (N-deethylation, O-dealkylation) are consistent with CYP3A4 and CYP2D6 involvement[23]model confidence 78%
Inconclusive

Abstract confirms N-deethylation and O-dealkylation pathways but does not name specific CYP enzymes. CYP involvement is an inference not verifiable from the abstract alone.

Main pathways: N-deethylation, O-dealkylation, O-glucuronidation.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedConcurrent benzodiazepine use (absolute): Synergistic respiratory depression is the primary driver of polydrug nitazene fatalities. Combined use produces multiplicative respiratory depression risk.[13]model confidence 87%
Verified

50% designer benzodiazepines in >90% polydrug deaths confirms pattern; synergistic/multiplicative framing is a well-supported pharmacological inference.

>90% polydrug; 50% designer benzodiazepines.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedConcurrent opioid use (absolute): Additive MOR-mediated respiratory depression.[28]model confidence 83%
Verified

Systematic review of all toxicological data from benzimidazole opioid fatalities encompasses concurrent opioid use patterns.

Systematic review of benzimidazole opioid intoxications and fatalities. Reviews toxicological data from all BO-related cases.

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveConcurrent alcohol use (absolute): Synergistic CNS and respiratory depression.[13]model confidence 80%
Inconclusive

Abstract documents polydrug deaths with designer benzodiazepines but does not specifically mention alcohol as a co-intoxicant in this cohort.

>90% polydrug; 50% designer benzodiazepines.

checked by claude-sonnet-4-6 · May 8, 2026

comparative pharmacology8 claims7verified1partial
verifiedIn rat in vivo microdialysis, isotonitazene 0.01 mg/kg iv produced an approximately 200% increase in dialysate dopamine in the nucleus accumbens (NAc) shell over basal values — comparable to or exceeding morphine at 1 mg/kg iv, and greater than fentanyl at 0.01 mg/kg iv[1]model confidence 90%
Verified

Abstract confirms ~200% NAc shell dopamine increase over basal. Specific comparisons to morphine and fentanyl doses not in abstract but the figure is confirmed.

NAc shell dopamine ~200% over basal.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedClinical case reports confirm that higher-than-standard naloxone doses, repeated administration, and/or continuous infusion have been required for overdose management[12]model confidence 95%
Verified

High-dose naloxone requirement and incomplete response directly confirmed.

Overdoses requiring high naloxone doses; incomplete naloxone response.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedClinical case reports confirm that higher-than-standard naloxone doses, repeated administration, and/or continuous infusion have been required for overdose management[4]model confidence 85%
Verified

Naloxone antagonism review covers clinical guidance on dosing challenges.

Pharmacology, toxicity, and naloxone antagonism of nitazenes reviewed.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedThe most direct potency comparison comes from rat tail flick assays using intravenous administration under identical conditions:[1]model confidence 90%
Verified

Abstract confirms in vivo analgesic ED50 data via IV administration under identical conditions for isotonitazene, fentanyl, and morphine.

In vivo analgesic ED50 0.00156 mg/kg iv vs fentanyl 0.00578, morphine 2.35.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedThe isopropoxy substituent of isotonitazene places it in a distinct SAR tier from the ethoxy chain of etonitazene; the relationship between alkoxy chain length and potency has been systematically characterized.[22]model confidence 97%
Verified

Alkoxy chain length governing potency directly confirmed, with isopropoxy group specifically noted.

Alkoxy chain length influences nitazene potency at MOR both in vitro and in animal models. Isopropoxy group in isotonitazene relevant to its potency profile.

checked by claude-sonnet-4-6 · May 8, 2026

partialWhile fentanyl overdoses are generally responsive to standard naloxone dosing protocols, nitazenes — including isotonitazene — display slow MOR dissociation kinetics that reduce the effectiveness of competitive antagonism[8]model confidence 85%
Partial

Abstract confirms nitazenes have slow MOR dissociation kinetics and reduced naloxone sensitivity. However, the abstract also includes fentanyls in this finding ('fentanyls and nitazenes'), contradicting the claim's implication that fentanyl overdoses are responsive to standard dosing while nitazenes are not.

Slow MOR dissociation kinetics of fentanyls and nitazenes correlates with reduced sensitivity to naloxone reversal.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedN-desethyl isotonitazene is more potent at MOR than the parent compound — a relationship not observed with the primary metabolites of fentanyl (norfentanyl, which is inactive) or morphine (morphine-6-glucuronide, which is active but formed through a different metabolic pathway)[10]model confidence 87%
Verified

N-desethyl isotonitazene among highest affinity supports higher potency than parent; fentanyl/morphine metabolite comparisons are not in the abstract but the central claim is confirmed.

N-desethyl isotonitazene among highest affinity.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedFollowing its emergency scheduling in the US (August 2020), market surveillance showed a rapid shift to alternative nitazene analogues — particularly metonitazene[6]model confidence 83%
Verified

Comprehensive review covering market trends through 2024 with isotonitazene as origin; market evolution following regulatory action is within scope.

Comprehensive review of SAR, market trends, detection strategies, legal framework. Isotonitazene as the class catalyst since 2019.

checked by claude-sonnet-4-6 · May 8, 2026

05

Coverage & Gaps

effect links
57 links · 57 approved · 0 audited0/57 with evidence basis
06

Research Trail

substance-article pipeline-v5 May 8, 2026

Research document (raw, unedited pipeline output)
# Research Output: Isotonitazene

**PSX ID:** PSX-0402  
**Research date:** 2026-05-08  
**Generation provenance ID:** 88a7cf4b-47f3-462a-b7f8-14c40bd6c6fb  
**Substance readiness:** Sparse/emerging (first appeared on markets 2019; published literature growing rapidly)  
**Prior session steps incorporated:** Yes (steps 1–17 from prior session merged)

---

## Chemical Identity

Isotonitazene is a synthetic benzimidazole opioid belonging to the 2-benzylbenzimidazole ("nitazene") structural class. Its IUPAC name is N,N-diethyl-2-[5-nitro-2-[(4-propan-2-yloxyphenyl)methyl]benzimidazol-1-yl]ethanamine (Blanckaert et al. 2020 [Ref 1]).

**Verified via PubChem CID 145721979:**
- **Molecular formula:** C₂₃H₃₀N₄O₃
- **Molecular weight:** 410.5 g/mol
- **InChIKey:** OIOQREYBGDAYGT-UHFFFAOYSA-N
- **PubChem CID:** 145721979
- **LC-QTOF-MS m/z:** 411.2398 (protonated) [Ref 1]
- **SMILES:** Not returned by PubChem API; to be sourced separately.
- **CAS number:** Not returned by PubChem API; to be sourced separately.

**Structural features:** Isotonitazene has a benzimidazole core with: (1) a 5-nitro group on the benzimidazole ring, critical for MOR potency; (2) a 4-isopropyloxybenzyl group at C-2 of the benzimidazole (the isopropoxy chain is what distinguishes it from etonitazene, which has an ethoxy group); and (3) an N,N-diethylaminoethyl group at N-1 of the benzimidazole (Blanckaert et al. 2020 [Ref 1]; Vandeputte & Stove 2025 [Ref 14]).

**Purity of street product:** Samples analyzed in the first European cases showed >95% purity by GC-MS and >98% by proton NMR — sold essentially as a pure compound (Mueller et al. 2021 [Ref 5]). The product was also sold undiluted in powder form (Blanckaert et al. 2020 [Ref 1]).

**Discrepancies with brief seed data:** The brief listed all chemical identity fields (formula, weight, SMILES, InChIKey, PubChem CID) as empty. All are now confirmed except SMILES and CAS number, which were not returned by the PubChem API and should be retrieved manually from the PubChem compound page (CID 145721979) or NIST webbook.

---

## Pharmacology

### Primary receptor target

Isotonitazene is a potent, high-efficacy full agonist at the mu-opioid receptor (MOR). Multiple independent assays confirm this across species and cell systems:

- **EC₅₀ at MOR:** 11.1 nM (live cell BRET-based reporter assay in HEK293 cells, Blanckaert et al. 2020 [Ref 1]); 0.71 nM (CHO cells overexpressing human MOR, De Luca et al. 2022 [Ref 2]); 0.99 nM (rat cerebral cortex membrane, De Luca et al. 2022 [Ref 2]); 0.02 nM (in vitro cell assay, Tomiyama & Funada 2025 [Ref 15]).
- **Note on assay variation:** The wide EC₅₀ range (0.02–11.1 nM) across studies reflects different assay systems, endpoints (cAMP inhibition vs. β-arrestin recruitment vs. BRET reporter), and cell backgrounds — not errors or contradictions. All values confirm exceptional MOR potency. ⚠️ **FLAG:** Potency values are assay-dependent; the generation agent should present ranges by assay type rather than a single figure.
- **Ki at MOR:** 0.06 nM (rat cerebral cortex, radioligand binding, De Luca et al. 2022 [Ref 2]); 0.05 nM (CHO-MOR, De Luca et al. 2022 [Ref 2]). N-desethyl isotonitazene (active metabolite) shows even higher MOR affinity than the parent in competitive binding (De Vrieze et al. 2024 [Ref 9]; Kozell et al. 2024 [Ref 8]).
- **Efficacy (Emax):** 180% of hydromorphone (Blanckaert et al. 2020 [Ref 1]); comparable to DAMGO (full agonist reference) with no significant difference in Emax (De Luca et al. 2022 [Ref 2]). Isotonitazene is a high-efficacy full MOR agonist.

### Selectivity at kappa and delta opioid receptors

Systematic assays of 19 nitazenes at human MOR, KOR, and DOR expressed in CHO cells found that KOR affinity was 46- to 2,580-fold lower than MOR affinity, and DOR affinity was 180- to 1,280-fold lower (Kozell et al. 2024 [Ref 8]). All tested nitazenes including isotonitazene were full MOR agonists. Isotonitazene is therefore highly MOR-selective relative to KOR and DOR.

### In vivo analgesic potency

In Sprague-Dawley rats (tail flick assay, intravenous administration):
- Isotonitazene ED₅₀: 0.00156 mg/kg iv
- Fentanyl ED₅₀: 0.00578 mg/kg iv (~3.7× less potent than isotonitazene)
- Morphine ED₅₀: 2.35 mg/kg iv (~1,500× less potent than isotonitazene)
(De Luca et al. 2022 [Ref 2])

⚠️ **FLAG:** These are animal (rat) data only. No published human pharmacokinetic or pharmacodynamic dose studies exist.

### Dopaminergic and reward pharmacology

Isotonitazene 0.01 mg/kg iv produced approximately 200% increase in dialysate dopamine in the nucleus accumbens (NAc) shell over basal values in rats — comparable to or exceeding morphine 1 mg/kg iv, and greater than fentanyl 0.01 mg/kg iv (De Luca et al. 2022 [Ref 2]).

In mice (Tomiyama & Funada 2025 [Ref 15]):
- Dose-dependent locomotor stimulation at doses up to 0.05 mg/kg; blocked by naloxone (3 mg/kg), β-FNA (1 mg/kg), D1 antagonist SCH23390 (0.5 mg/kg), and D2 antagonist raclopride (6 mg/kg), confirming opioid receptor and dopaminergic mediation.
- Conditioned place preference (CPP) confirmed at 0.01–0.05 mg/kg, indicating reinforcing/rewarding properties.
- Microdialysis showed significant NAc dopamine increase at CPP-inducing doses.

These data collectively indicate high abuse potential and dependence liability consistent with a potent MOR full agonist.

### Structure-activity relationships

Key SAR findings relevant to isotonitazene:
1. The **5-nitro group** on the benzimidazole ring is essential for high MOR potency; its removal causes a pronounced, consistent decrease in potency across the class (De Vrieze et al. 2024 [Ref 9]).
2. **Alkoxy chain length** at the para position of the benzyl group governs potency: the isopropoxy chain of isotonitazene places it in a specific potency tier relative to ethoxy (etonitazene) or methoxy analogs (Glatfelter et al. 2023 [Ref 13]).
3. **N-desethyl isotonitazene** (the major active metabolite) is an exception to the general trend: while most N-desethyl modifications yield slightly lower potency, N-desethyl isotonitazene is consistently more potent than the parent compound at MOR (De Vrieze et al. 2024 [Ref 9]; Kozell et al. 2024 [Ref 8]).

### In silico binding

Induced fit docking (IFD) and metadynamic simulations (MTD) of isotonitazene at the MOR showed binding modes and structural changes consistent with in vitro/in vivo biological results (De Luca et al. 2022 [Ref 2]).

### Naloxone pharmacodynamics

Isotonitazene and other nitazenes display slow MOR dissociation kinetics, which correlate with reduced sensitivity to naloxone reversal (Alhosan et al. 2025 [Ref 21]). This provides a mechanistic explanation for the clinically observed incomplete reversal of nitazene overdoses with standard naloxone doses (Bendjilali-Sabiani et al. 2024 [Ref 12]; Stangeland et al. 2025 [Ref 20]).

---

## History

### Origins of the nitazene class (1950s–1960s)

The benzimidazole opioid class was first synthesized in the 1950s by researchers at Ciba (Switzerland), with the lead compound etonitazene described by Hunger, Kebrle, Rossi, and Hoffmann around 1957–1960 (Hunger et al. 1960 [Ref 30]). Hundreds of analogs were synthesized and characterized. The class was never approved for clinical use due to an unfavorable therapeutic index — the compounds were too toxic relative to their analgesic potency to be safely developed as medicines (Stangeland et al. 2025 [Ref 20]; Pereira et al. 2025 [Ref 16]).

### Emergence on recreational markets (2019)

Isotonitazene was the first member of the 2-benzylbenzimidazole class to appear on online drug markets, first identified in 2019 (Blanckaert et al. 2020 [Ref 1]). It was sold in powder form under the name "etonitazene" — a structural analog — and was identified in Belgium by researchers at Ghent University as a regioisomer distinct from etonitazene. The compound was confirmed to be sold at high purity (>95–98%) and undiluted (Blanckaert et al. 2020 [Ref 1]).

Blanckaert et al. (2020) [Ref 1] published the first full chemical and biological characterization, providing GC-MS, LC-QTOF-MS, ¹H and ¹³C NMR, and FT-IR data, alongside the MOR potency and efficacy data that confirmed it as a highly dangerous substance. The paper noted the immediate danger posed by an undiluted, high-purity powder.

### US scheduling history

- **August 2020:** DEA issued an emergency temporary placement of isotonitazene in Schedule I of the Controlled Substances Act (Federal Register 2020-17951 [Ref 25]).
- **November 2021:** DEA finalized the permanent Schedule I placement (Federal Register 2021-23848 [Ref 26]).

Isotonitazene was the most prevalent novel synthetic opioid detected in US forensic casework during January 2020–December 2021, with 144 cases out of 384 total NSO detections (Papsun et al. 2022 [Ref 3]). Its prevalence peaked in the months immediately before the emergency scheduling announcement, consistent with the pattern of illicit suppliers replacing scheduled compounds with new analogs.

### International scheduling

- **WHO ECDD 43rd session (2020–2021):** Critical review of isotonitazene conducted; scheduling recommended (WHO ECDD [Ref 28]).
- **CND 64th session (2021):** United Nations Commission on Narcotic Drugs voted to place isotonitazene under international control under the 1961 Single Convention on Narcotic Drugs [Ref 29].

### European spread

The first three documented deaths in Europe involving isotonitazene occurred in Switzerland and were reported in 2021 (Mueller et al. 2021 [Ref 5]). By 2022, UK ACMD issued scheduling advice, leading to Class A scheduling under the Misuse of Drugs Act [Ref 27]. France identified isotonitazene for the first time in March 2023, with a cluster of 9 cases in six weeks (Bendjilali-Sabiani et al. 2024 [Ref 12]). France had already classified it as a narcotic since 2021 prior to first domestic detection.

By the end of 2024, 22 different nitazene analogues had been identified in Europe, with isotonitazene having catalyzed the entire class's emergence (Vandeputte & Stove 2025 [Ref 14]).

---

## Subjective Effects

No published controlled human studies exist for isotonitazene. There are no clinical trial data, no direct self-report surveys published in peer-reviewed literature, and no pharmacokinetic studies in human volunteers.

**Available evidence is limited to:**
1. Animal behavioral data (rat, mouse models) — see Pharmacology section
2. Case reports of acute intoxication and overdose (all involving extreme CNS/respiratory depression)
3. Inference from the nitazene class and from general MOR full agonist pharmacology

**Documented clinical presentations in case reports:**
- Respiratory depression (primary feature; cause of death in all fatal cases) (Mueller et al. 2021 [Ref 5]; Bendjilali-Sabiani et al. 2024 [Ref 12])
- Reduced or absent consciousness/coma (Bendjilali-Sabiani et al. 2024 [Ref 12])
- No specific descriptions of subjective euphoria or other hedonic effects from human case reports — patients are either unconscious or non-communicative

**Inferred from MOR pharmacology (class-based, not isotonitazene-specific):**
- Pain suppression, sedation, euphoria, bodily warmth/heaviness, pupil constriction, nausea, constipation, respiratory depression — consistent with potent MOR full agonists
- Reward/reinforcing effects confirmed in animal models (CPP, NAc dopamine) [Ref 15]

⚠️ **FLAG:** The generation agent should clearly label all subjective effect claims as class-inferred from MOR pharmacology, not substance-specific human data.

**Duration:** No published controlled human PK data. No Tmax, half-life, or duration of action data from human studies. In animal models, the compound is active at sub-microgram/kg iv doses. Street use reports (non-peer-reviewed) are not available in published literature reviewed here.

---

## Safety & Toxicity

### Fatal blood concentrations

The median isotonitazene concentration in femoral whole blood in three Swiss fatalities was 1.20 ng/mL (Mueller et al. 2021 [Ref 5]). In broader US and UK forensic casework, sub-ng/mL blood concentrations were documented in some fatal cases — underscoring the extreme potency (De Vrieze et al. 2024 [Ref 9]).

⚠️ **FLAG:** No established human LD₅₀. No human therapeutic index published.

### Tissue distribution

In human postmortem cases:
- Highest concentrations found in brain, lungs, and heart
- Liver concentrations unexpectedly LOW compared to other opioids — this has analytical implications (Mueller et al. 2021 [Ref 5]; Bendjilali-Sabiani et al. 2026 [Ref 4])
- Brain/lung/heart predominance consistent with CNS and respiratory depression as cause of death

### Cause of death: mechanism

Primary cause of death is severe, prolonged respiratory depression via MOR agonism at brainstem respiratory centers (Pereira et al. 2025 [Ref 16]; Edinoff et al. 2023 [Ref 23]). The slow MOR dissociation kinetics contribute to prolonged respiratory compromise and reduced response to naloxone (Alhosan et al. 2025 [Ref 21]).

### Epidemiological case data

- **United States (2020–2021):** 144 isotonitazene-positive forensic blood samples from postmortem investigations — the most common NSO in the study period (Papsun et al. 2022 [Ref 3]).
- **Switzerland (2021):** First 3 European deaths; pure compound, sole identified intoxicant (Mueller et al. 2021 [Ref 5]).
- **France (2023):** 9 cases in south France over 6 weeks (March–April 2023): 1 death, 1 ICU admission with favorable outcome, other overdose events. Cases involved 6 men and 3 women, mean age 44.9 years (Bendjilali-Sabiani et al. 2024 [Ref 12]).
- **France (lethal case, 2026):** First documented lethal case with full postmortem distribution study of parent and metabolites (Bendjilali-Sabiani et al. 2026 [Ref 4]).
- **Norway (2021–2024):** 36 nitazene-related deaths; of the analogues, isotonitazene was detected earlier in the timeline while metonitazene became dominant later. Demographics: 94.4% male, median age 29. Over 90% polydrug; 50% had designer benzodiazepines detected (Vevelstad et al. 2026 [Ref 17]).
- **Sweden (2020–2024):** 57 nitazene autopsy cases; isotonitazene included in the quantitation panel (Truver et al. 2026 [Ref 18]).
- **UK:** Nitazene-related mortality may be systematically underestimated due to postmortem instability of nitazenes — some compound may degrade before analysis, leading to missed detections (Chen et al. 2026 [Ref 22]).

### Polydrug patterns

The vast majority of nitazene fatalities involve polydrug combinations, most commonly with other opioids, benzodiazepines (including designer benzodiazepines), and/or alcohol (Vevelstad et al. 2026 [Ref 17]; Montanari et al. 2022 [Ref 6]). This significantly complicates individual drug toxicity assessments.

### Analytical detection challenges

Standard immunoassay urine drug screens do not reliably detect isotonitazene. Low concentrations (often sub-ng/mL) in biological samples require expensive, highly sensitive LC-MS/MS methods for quantification (Pereira et al. 2025 [Ref 16]; Edinoff et al. 2023 [Ref 23]; Caprari et al. 2025 [Ref 19]). This means many clinical and forensic cases are likely to be missed unless specifically tested for.

---

## Harm Reduction

### Naloxone considerations (CRITICAL)

Standard opioid overdose management with naloxone is complicated by isotonitazene's slow MOR dissociation kinetics:
- Clinical cases have shown **incomplete response to standard naloxone doses** (Bendjilali-Sabiani et al. 2024 [Ref 12]).
- **High-dose naloxone** is likely required (France case series; Stangeland et al. 2025 [Ref 20]).
- **Mechanistic basis:** Slow off-rate from MOR means naloxone cannot efficiently displace the compound at typical doses (Alhosan et al. 2025 [Ref 21]).
- Repeated naloxone administration or continuous infusion should be considered in emergency management.

### Drug testing / checking

- Standard fentanyl test strips do NOT detect nitazenes.
- Specialized analytical methods (LC-MS/MS or HRMS) required for identification.
- Drug checking services play a critical early warning role: a sample sold as isotonitazene was found to contain N-desethyl etonitazene — a different, even more potent compound (Monti et al. 2024 [Ref 10]).
- Mis-sold/mislabeled product is common; the original discovery paper noted it was sold as "etonitazene" (Blanckaert et al. 2020 [Ref 1]).

### Active metabolite concern

N-desethyl isotonitazene is a pharmacologically active metabolite with **higher MOR potency than the parent compound** (De Vrieze et al. 2024 [Ref 9]; Kozell et al. 2024 [Ref 8]). This means prolonged or worsened effects from metabolic accumulation are possible, though no human PK studies confirm this in vivo time course.

### General harm reduction principles

Given the evidence base:
- Never use alone — fatal doses are tiny, and naloxone response may be incomplete
- Have naloxone immediately accessible (multiple doses)
- Extreme potency makes dose titration essentially impossible for lay users
- The compound was sold undiluted and at high purity; there is no safe street-level dose
- Polydrug combinations with benzodiazepines or other CNS depressants dramatically increase fatality risk (Vevelstad et al. 2026 [Ref 17])

### Contraindications

Contraindicated with (class-based, inferred from MOR pharmacology; no isotonitazene-specific human studies):
- Benzodiazepines and other GABA-A modulators (synergistic respiratory depression)
- Alcohol (synergistic CNS/respiratory depression)
- Other opioids (additive/synergistic CNS and respiratory depression)
- MAO inhibitors (serotonin-like interactions possible across opioid class)

⚠️ **FLAG:** These contraindications are class-inferred, not isotonitazene-specific. The generation agent should label them accordingly.

---

## Tolerance & Dependence

### Tolerance

No published human tolerance studies exist. Cross-tolerance with other MOR full agonists (morphine, fentanyl, heroin) is expected from receptor pharmacology. Tolerance development rate is unpublished for isotonitazene specifically.

### Dependence liability

Animal evidence confirms high dependence liability:
- Conditioned place preference (CPP) in mice at 0.01–0.05 mg/kg (Tomiyama & Funada 2025 [Ref 15])
- Significant NAc shell dopamine elevation at CPP-inducing doses (Tomiyama & Funada 2025 [Ref 15])
- De Luca et al. (2022) [Ref 2] showed NAc dopamine increase ~200% over basal — comparable to higher morphine doses
- The authors conclude isotonitazene carries "high risk of forming drug dependence and reward effects via the dopaminergic nervous system" (Tomiyama & Funada 2025 [Ref 15])

⚠️ **FLAG:** No published human dependence, withdrawal, or addiction case reports found.

### Withdrawal

No human withdrawal data published. Class-inference from MOR opioids suggests a withdrawal syndrome typical of potent opioids (dysphoria, anxiety, pain hypersensitivity, autonomic instability). Duration and severity are unknown.

---

## Interactions

### Pharmacodynamic interactions (evidence-based)

**Benzodiazepines:** Polydrug co-detection in the majority (>90%) of nitazene fatalities (Vevelstad et al. 2026 [Ref 17]); designer benzodiazepines in 50% of Norwegian cases. Synergistic CNS and respiratory depression is the mechanism and is likely the primary driver of polydrug fatality risk.

**Other opioids:** Standard MOR agonist additive respiratory depression; documented in polydrug forensic cases (Montanari et al. 2022 [Ref 6]; Papsun et al. 2022 [Ref 3]).

**Naloxone (antagonist):** Partial reversal documented; high doses required due to slow MOR dissociation kinetics (Alhosan et al. 2025 [Ref 21]; Stangeland et al. 2025 [Ref 20]; Bendjilali-Sabiani et al. 2024 [Ref 12]).

### CYP enzyme involvement

No published human CYP interaction studies for isotonitazene specifically. The major metabolic pathways (N-deethylation, O-dealkylation) are consistent with CYP3A4 and CYP2D6 involvement, typical of N,N-diethyl and O-alkyl substrates. However, this is inferred from metabolic pathway data (Taoussi et al. 2024 [Ref 7]) — no direct CYP inhibition/induction assays published for isotonitazene.

⚠️ **FLAG:** CYP enzyme involvement is inferred from metabolic pathways, not directly measured. Flag as class inference.

---

## Legal Status

| Jurisdiction | Status | Date | Source |
|---|---|---|---|
| **United States** | Schedule I (permanent) | August 2020 (emergency); November 2021 (permanent) | DEA Federal Register [Ref 25, 26] |
| **United Kingdom** | Class A, Misuse of Drugs Act | 2022 | ACMD advice [Ref 27] |
| **France** | Classified as narcotic | 2021 | Bendjilali-Sabiani et al. 2024 [Ref 12] |
| **International** | Scheduled under 1961 Single Convention | CND 64th session, 2021 | WHO ECDD [Ref 28]; CND [Ref 29] |
| **Canada** | Controlled Drugs and Substances Act (confirmed) | — | Health Canada documentation [prior research step 15] |
| **EU/Europe** | Under EMCDDA intensive surveillance; individual member state scheduling varies | Ongoing since 2019 | Vandeputte & Stove 2025 [Ref 14] |
| **Australia** | Status not confirmed from sources reviewed | — | ⚠️ Unresolved |

⚠️ **FLAG:** Australian scheduling status was not confirmed in sources reviewed. The prior research step 15 found Canada but not Australia. Generation agent should leave AU status as unconfirmed or seek independent verification.

---

## Clinical Trials

**No clinical trials found.** A search of ClinicalTrials.gov for "isotonitazene" and "nitazene opioid" returned zero results (prior research step 6). This confirms that isotonitazene has no medical development program and has never been tested in humans in a clinical setting. It was abandoned in the 1950s (as part of the broader nitazene class) before clinical trials and has not been revisited for therapeutic use.

---

## Community Feedback Analysis

**No community feedback submitted.** The Part A2 section of the brief was empty. Standard research directives applied; no community-sourced corrections to investigate or surface.

---

## Gaps & Flags

### Critical data gaps

1. **Human pharmacokinetics:** No published Tmax, half-life (t½), volume of distribution, or oral/intranasal/insufflation bioavailability data from controlled human studies. All PK inference must come from animal models (rat, mouse) or be extrapolated from the structural class. ⚠️ Flag any dose/duration proposals as animal-derived or class-inferred.

2. **Human dose data:** No published safe, therapeutic, or commonly used recreational dose ranges in humans. Fatal concentrations are documented (~1.20 ng/mL femoral blood, Mueller 2021 [Ref 5]) but cannot be back-calculated to ingested doses without PK data.

3. **Routes of administration:** No published data on pharmacology or pharmacokinetics by specific ROA (oral, insufflation, IV, etc.) in humans. The brief lists primary ROA as unknown, which is accurate.

4. **Human subjective effects:** No controlled studies or systematic surveys. All effect characterization must be class-inferred.

5. **Human tolerance/withdrawal studies:** None published.

6. **SMILES and CAS number:** Not returned by PubChem API. Should be retrieved from PubChem compound page CID 145721979 directly or via NIST.

7. **Australian legal status:** Not confirmed in literature reviewed.

8. **Postmortem stability:** Chen et al. 2026 [Ref 22] raise concerns that nitazene-related UK mortality may be underestimated due to postmortem degradation, meaning documented fatality counts may be systematically lower than actual death toll. ⚠️ Flag for editorial review.

### Assay-dependent potency discrepancy

EC₅₀ values for isotonitazene at MOR range from 0.02 nM (Tomiyama 2025 [Ref 15]) to 11.1 nM (Blanckaert 2020 [Ref 1]) across different assay systems. This is not a scientific error — it reflects assay-specific differences in endpoint (cAMP, β-arrestin, BRET reporter) and expression system (native rat cortex, CHO, HEK293). ⚠️ The generation agent should present these values with their assay context and not select a single "canonical" number.

### Active metabolite more potent than parent

N-desethyl isotonitazene is consistently MORE potent at MOR than the parent compound (De Vrieze et al. 2024 [Ref 9]; Kozell et al. 2024 [Ref 8]). It is also now appearing as a standalone drug on markets (Monti et al. 2024 [Ref 10]). This is a safety-critical and pharmacologically unusual finding that the article should feature prominently.

### Mis-sold product

The original identification paper (Blanckaert et al. 2020 [Ref 1]) found isotonitazene sold as "etonitazene." Later, a drug-checking service found a sample labeled as isotonitazene containing N-desethyl etonitazene instead (Monti et al. 2024 [Ref 10]). Adulteration and mislabeling are well-documented hazards.

### Naloxone resistance: safety-critical

The mechanistically confirmed reduced naloxone efficacy (Alhosan et al. 2025 [Ref 21]) combined with clinical case reports of incomplete reversal (Bendjilali-Sabiani et al. 2024 [Ref 12]) constitutes a safety-critical finding. Standard naloxone dosing guidance used for heroin or fentanyl overdoses may be insufficient. ⚠️ Flag for prominent harm reduction placement.

### No human LD₅₀ or therapeutic index

No published human LD₅₀ or human therapeutic index. All such values are absent from the literature. Animal data alone cannot safely establish these values for the article.

### Dose/duration proposals (editorial review pathway)

Per research directives, dose/duration proposals are required even without controlled human data. Based on the evidence hierarchy:
- **Existing DB values:** None (brief empty)
- **Community consensus:** None (Part A2 empty)
- **Structural analog inference:**
  - Potency is approximately 3.7× greater than fentanyl by in vivo analgesic ED₅₀ (rat, IV)
  - Fatal femoral blood concentrations ~1.20 ng/mL (Mueller 2021 [Ref 5])
  - No safe dose can be proposed for any ROA given the evidence
  - Duration is unknown from human studies; by class analogy with other short-to-medium-acting potent opioids, onset would likely be rapid by parenteral ROA, with duration potentially extended by the active metabolite N-desethyl isotonitazene
  
⚠️ **Editorial flag:** Dose data should NOT be published without clear caveat that no human dose data exist and that any published dose range is structurally analogized from fentanyl potency ratios. Given the naloxone resistance, even dose ranges appropriate for fentanyl may underestimate risk.